0001493152-17-014602.txt : 20171214 0001493152-17-014602.hdr.sgml : 20171214 20171214161100 ACCESSION NUMBER: 0001493152-17-014602 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 47 CONFORMED PERIOD OF REPORT: 20171031 FILED AS OF DATE: 20171214 DATE AS OF CHANGE: 20171214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PURE BIOSCIENCE, INC. CENTRAL INDEX KEY: 0001006028 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS CHEMICAL PRODUCTS [2890] IRS NUMBER: 330530289 STATE OF INCORPORATION: DE FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-14468 FILM NUMBER: 171256300 BUSINESS ADDRESS: STREET 1: 1725 GILLESPIE WAY CITY: EL CAJON STATE: CA ZIP: 92020 BUSINESS PHONE: 619-596-8600 MAIL ADDRESS: STREET 1: 1725 GILLESPIE WAY CITY: EL CAJON STATE: CA ZIP: 92020 FORMER COMPANY: FORMER CONFORMED NAME: PURE BIOSCIENCE DATE OF NAME CHANGE: 20031029 FORMER COMPANY: FORMER CONFORMED NAME: PURE BIOSCIENCES DATE OF NAME CHANGE: 20031029 FORMER COMPANY: FORMER CONFORMED NAME: INNOVATIVE MEDICAL SERVICES DATE OF NAME CHANGE: 19960122 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

[X]	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED OCTOBER 31, 2017

[ ]	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934

Commission File Number 001-14468

PURE Bioscience, Inc.

(Exact name of registrant as specified in its charter)

Delaware	33-0530289
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

1725 Gillespie Way

El Cajon, California

92020

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (619) 596-8600

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	[ ]	Accelerated filer	[ ]

Non-accelerated filer	[ ]	Smaller reporting company	[X]

Emerging growth company	[ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X]

As of December 12, 2017, there were 67,981,861 shares of the registrant’s common stock, $0.01 par value per share, outstanding.

PURE Bioscience, Inc.

Form 10-Q

for the Quarterly Period Ended October 31, 2017

Table of Contents

		Page
PART I	FINANCIAL INFORMATION
Item 1.	Financial Statements	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	22
Item 4.	Controls and Procedures	23

PART II	OTHER INFORMATION
Item 1.	Legal Proceedings	24
Item 1A.	Risk Factors	24
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	24
Item 3.	Defaults Upon Senior Securities	24
Item 4.	Mine Safety Disclosures	24
Item 5.	Other Information	24
Item 6.	Exhibits	25
	Signatures	27

Part I - Financial Information

Item 1. Financial Statements

PURE Bioscience, Inc.

Condensed Consolidated Balance Sheets

	October 31, 2017			July 31, 2017
	(Unaudited)
Assets
Current assets
Cash and cash equivalents	$	3,229,000		$	1,640,000
Accounts receivable		143,000			297,000
Inventories, net		274,000			273,000
Restricted cash		75,000			75,000
Prepaid expenses		175,000			174,000
Total current assets		3,896,000			2,459,000
Property, plant and equipment, net		530,000			548,000
Patents, net		781,000			822,000
Total assets	$	5,207,000		$	3,829,000
Liabilities and stockholders’ equity
Current liabilities
Accounts payable	$	425,000		$	426,000
Accrued liabilities		212,000			249,000
Derivative liabilities		—			1,853,000
Total current liabilities		637,000			2,528,000
Deferred rent		10,000			11,000
Total liabilities		647,000			2,539,000
Commitments and contingencies
Stockholders’ equity
Preferred stock, $0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding
Common stock, $0.01 par value: 100,000,000 shares authorized, 67,981,861 shares issued and outstanding at October 31, 2017, and 63,093,153 shares issued and outstanding at July 31, 2017		680,000			631,000
Additional paid-in capital		115,701,000			110,141,000
Accumulated deficit		(111,821,000	)		(109,482,000	)
Total stockholders’ equity		4,560,000			1,290,000
Total liabilities and stockholders’ equity	$	5,207,000		$	3,829,000

See accompanying notes.

PURE Bioscience, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

	Three months ended
	October 31,
	2017			2016
Net product sales	$	464,000		$	531,000
Operating costs and expenses
Cost of goods sold		146,000			265,000
Selling, general and administrative		1,445,000			1,337,000
Research and development		144,000			248,000
Share-based compensation		656,000			278,000
Total operating costs and expenses		2,391,000			2,128,000
Loss from operations		(1,927,000	)		(1,597,000	)
Other income (expense)
Change in derivative liabilities		459,000			(159,000	)
Inducement to exercise warrants		(876,000	)		—
Interest expense, net		(1,000	)		(1,000	)
Other income, net		6,000			14,000
Total other expense		(412,000	)		(146,000	)
Net loss	$	(2,339,000	)	$	(1,743,000	)
Basic and diluted net loss per share	$	(0.04	)	$	(0.03	)
Shares used in computing basic and diluted net loss per share		64,964,404			64,823,917

See accompanying notes.

PURE Bioscience, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	Three Months Ended
	October 31,
	2017			2016
Operating activities
Net loss	$	(2,339,000	)	$	(1,743,000	)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation		656,000			278,000
Amortization of stock issued for services		39,000			36,000
Depreciation and amortization		71,000			65,000
Change in fair value of derivative liability		(459,000	)		159,000
Inducement to exercise warrants		876,000			—
Changes in operating assets and liabilities:
Accounts receivable		154,000			117,000
Inventories		(1,000	)		2,000
Prepaid expenses		11,000			(108,000	)
Accounts payable and accrued liabilities		(38,000	)		147,000
Deferred rent		(1,000	)		—
Net cash used in operating activities		(1,031,000	)		(1,047,000	)
Investing activities
Investment in patents		(3,000	)		(7,000	)
Purchases of property, plant and equipment		(9,000	)		(76,000	)
Net cash used in investing activities		(12,000	)		(83,000	)
Financing activities
Net proceeds from the exercise of warrants		2,632,000			—
Net cash provided by financing activities		2,632,000			—
Net (decrease) increase in cash and cash equivalents		1,589,000			(1,130,000	)
Cash and cash equivalents at beginning of period		1,640,000			5,194,000
Cash and cash equivalents at end of period	$	3,229,000		$	4,064,000
Supplemental disclosure of cash flow information
Cash paid for taxes	$	—		$	2,000
Warrant liabilities removed due to settlements	$	1,394,000		$	—
Common stock issued for prepaid services	$	51,000		$	—

See accompanying notes.

PURE Bioscience, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements include the consolidated accounts of PURE Bioscience, Inc. and its wholly owned subsidiary, ETI H2O Inc., a Nevada corporation. ETI H2O, Inc. currently has no business operations and no material assets or liabilities and there have been no significant transactions related to ETI H2O, Inc. during the periods presented in the condensed consolidated financial statements. All inter-company balances and transactions have been eliminated. All references to “PURE,” “we,” “our,” “us” and the “Company” refer to PURE Bioscience, Inc. and our wholly owned subsidiary.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, for interim financial information pursuant to the instructions to Form 10-Q and Article 10/Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the quarter ended October 31, 2017 are not necessarily indicative of the results that may be expected for other quarters or the year ending July 31, 2018. The July 31, 2017 balance sheet was derived from audited financial statements but does not include all disclosures required by GAAP and included in our Annual Report on Form 10-K. For more complete information, these unaudited financial statements and the notes thereto should be read in conjunction with the audited financial statements for the year ended July 31, 2017 included in our Annual Report on Form 10-K covering such period filed with the Securities and Exchange Commission, or SEC, on October 26, 2017.

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.

2. Liquidity & Going Concern Uncertainty

These unaudited condensed consolidated financial statements have been prepared and presented on a basis assuming we will continue as a going concern. The factors below raise substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty.

Since our inception, we have financed our operations primarily through public and private offerings of securities, debt financing, and revenue from product sales and license agreements. We have a history of recurring losses, and as of October 31, 2017, we have incurred a cumulative net loss of $111,821,000.

We do not have, and may never have, significant cash inflows from product sales or from other sources of revenue to fund our operations. As of October 31, 2017, we had $3,229,000 in cash and cash equivalents, and $425,000 of accounts payable. As of October 31, 2017, we have no long-term debt. We do not currently believe that our existing cash resources are sufficient to meet our anticipated needs over the next twelve months from the date hereof.

Our future capital requirements depend on numerous forward-looking factors. These factors may include, but are not limited to, the following: the acceptance of, and demand for, our products; our success and the success of our partners in selling our products; our success and the success of our partners in obtaining regulatory approvals to sell our products; the costs of further developing our existing products and technologies; the extent to which we invest in new product and technology development; and the costs associated with the continued operation, and any future growth, of our business. The outcome of these and other forward-looking factors will substantially affect our liquidity and capital resources.

Until we can generate significant cash from operations, we expect to continue to fund our operations with the proceeds of offerings of our equity and debt securities. However, we cannot assure you that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business. Further, any contracts or license arrangements we enter into to raise funds may require us to relinquish our rights to our products or technology, and we cannot assure you that we will be able to enter into any such contracts or license arrangements on acceptable terms, or at all. Having insufficient funds may require us to delay or scale back our marketing, distribution and other commercialization activities or cease our operations altogether.

We do not have any unused credit facilities or other sources of capital available to us at this time. We intend to secure additional working capital through sales of additional debt or equity securities. Our intended financing initiatives are subject to risk, and we cannot provide any assurance about the availability or terms of these or any future financings.

If we are unable to obtain sufficient capital, it will have a material adverse effect on our business and operations. It could cause us to fail to execute our business plan, fail to take advantage of future opportunities, or fail to respond to competitive pressures or customer requirements. It also may require us to significantly modify our business model and operations to reduce spending to a sustainable level, which may include delaying, scaling back or eliminating some or all of our ongoing and planned investments in corporate infrastructure, research and development projects, regulatory submissions, business development initiatives, and sales and marketing activities, among other investments. If adequate funds are not available when needed, we may be required to reduce or cease operations altogether.

The condensed consolidated financial statements do not include any adjustment relating to recoverability or classification of recorded assets and classification of recorded liabilities.

3. Net Loss Per Share

Basic net loss per common share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Our diluted net loss per common share is the same as our basic net loss per common share because we incurred a net loss during each period presented, and the potentially dilutive securities from the assumed exercise of all outstanding stock options, restricted stock units, and warrants would have an anti-dilutive effect. As of October 31, 2017 and 2016, the number of shares issuable upon the exercise of stock options, the vesting of restricted stock units, and the exercise of warrants, none of which are included in the computation of basic net loss per common share, was 11,680,939 and 10,719,394, respectively.

4. Comprehensive Loss

Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on marketable securities and foreign currency translation adjustments. For the three months ended October 31, 2017 and 2016, our comprehensive loss consisted only of net loss.

5. Inventory

Inventories are stated at the lower of cost or net realizable value, and net of a valuation allowance for potential excess or obsolete material. Cost is determined using the average cost method. Depreciation related to manufacturing is systematically allocated to inventory produced, and expensed through cost of goods sold at the time inventory is sold.

Inventories consist of the following:

	October 31, 2017		July 31, 2017
Raw materials	$	80,000	$	82,000
Finished goods		194,000		191,000
	$	274,000	$	273,000

6. Impairment of Long-Lived Assets

In accordance with GAAP, if indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the carrying value of the asset to the fair value of the asset and we record the impairment as a reduction in the carrying value of the related asset and a charge to operating results. Estimating the undiscounted future cash flows associated with long-lived assets requires judgment, and assumptions could differ materially from actual results. During the three months ended October 31, 2017, no impairment of long-lived assets was indicated or recorded.

7. Fair Value of Financial Instruments

Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the authoritative guidance establishes a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

	●	Level 1 – Quoted prices in active markets for identical assets or liabilities.

	●	Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

	●	Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

In connection with the October and November 2015 Private Placements, we issued warrants with derivative features. These instruments were accounted for as derivative liabilities (See Note 8 to these condensed consolidated financial statements).

We used Level 3 inputs for the valuation methodology of the derivative liabilities. The estimated fair values were computed using a Monte Carlo option pricing model based on various assumptions. Our derivative liabilities are adjusted to reflect estimated fair value at each period end, with any decrease or increase in the estimated fair value being recorded in other income or expense accordingly, as adjustments to the fair value of the derivative liabilities. Various factors are considered in the pricing models we use to value the warrants, including the Company’s current stock price, the remaining life of the warrants, the volatility of the Company’s stock price, and the risk free interest rate.

The following table provides a reconciliation of the beginning and ending balances of the derivative liabilities for the three months ended October 31, 2017:

Fair Value of Significant Unobservable Inputs (Level 3)

	Warrant
	Liabilities
Balance at July 31, 2017	$	1,853,000
Issuances		—
Settlement of warrant liabilities		(1,394,000	)
Adjustments to estimated fair value		(459,000	)
Balance at October 31, 2017	$	—

8. Derivative Liabilities

On October 23, 2015, we completed a first closing of a private placement financing (the “2015 Private Placement Financing”), where we issued, among other securities, a warrant to purchase up to an aggregate of 6,666,666 shares of common stock with a term of five years and a warrant to purchase up to an aggregate of 8,666,666 shares of common stock with a term of six months.

On November 23, 2015, we completed a second and final closing of the 2015 Private Placement Financing, where we issued, among other securities, a warrant to purchase up to an aggregate of 2,222,217 shares of common stock with a term of five years and a warrant to purchase up to an aggregate of 2,820,670 shares of common stock with a term of six months.

We accounted for the combined 20,376,219 warrants issued in connection with the 2015 Private Placement Financing in accordance with the accounting guidance for derivatives. The applicable accounting guidance sets forth a two-step model to be applied in determining whether a financial instrument is indexed to an entity’s own stock, which would qualify such financial instruments for a scope exception. This scope exception specifies that a contract that would otherwise meet the definition of a derivative financial instrument would not be considered as such if the contract is both (i) indexed to the entity’s own stock and (ii) classified in the stockholders’ equity section of the entity’s balance sheet. We determined the warrants were ineligible for equity classification due to anti-dilution provisions set forth therein.

During the fiscal year ended July 31, 2016, (i) all 2,820,670 of the six-month warrants issued in the second and final closing were exercised, (ii) the six-month warrants issued in the first closing expired and (iii) the five-year warrants issued in the first closing were cancelled.

On September 25, 2017, we completed the first closing of a tender offer to amend and exercise outstanding warrants to purchase shares of our common stock. As a result, 1,599,135 warrants issued in connection with the 2015 Private Placement Financing were exercised. In addition, there was a net exercise on 118,057 warrants which resulted in the issuance of 63,811 shares of our common stock. The net exercised warrants were issued in connection with the 2015 Private Placement Financing. The change in fair value of the warrant liabilities on September 25, 2017 was recorded as a change in derivative liabilities in the condensed consolidated statements of operations. The fair value on the exercise date was returned to additional paid in capital and is reflected in the settlement of warrant liability section on the table in Note 8. The following assumptions were used as inputs to the fair value model at September 25, 2017: stock price of $1.00 per share and a warrant exercise price of $0.45 per share as of the valuation date; our historical stock price volatility of 70.00%; risk free interest rate on U.S. treasury notes of 1.6%; warrant expiration of 3.2 years (See Note 10 to these condensed consolidated financial statements).

On October 10, 2017, we completed a second and final closing of a tender offer to amend and exercise outstanding warrants to purchase shares of our common stock. As a result, 268,909 warrants issued in connection with the 2015 Private Placement Financing were exercised. The change in fair value of the warrant liabilities on October 10, 2017 was recorded as a change in derivative liabilities in the condensed consolidated statements of operations. The fair value on the exercise date was returned to additional paid in capital and is reflected in the settlement of warrant liability section on the table in Note 8. The following assumptions were used as inputs to the fair value model at October 10, 2017: stock price of $1.03 per share and a warrant exercise price of $0.45 per share as of the valuation date; our historical stock price volatility of 70.00%; risk free interest rate on U.S. treasury notes of 1.6%; warrant expiration of 3.1 years (See Note 10 to these condensed consolidated financial statements).

During the three months ended October 31, 2017, all warrants containing derivative features issued in connection with the 2015 Private Placement Financing were exercised.

As of October 31, 2017, the total value of the derivative liabilities was zero. The change in fair value of the warrant liabilities for the three months ended October 31, 2017 and 2016, was a decrease of $459,000 and an increase of $159,000, respectively, which was recorded as a change in derivative liabilities in the condensed consolidated statements of operations.

9. Stockholders’ Equity

Preferred Stock

As of October 31, 2017, the Company’s Board of Directors is authorized to issue 5,000,000 shares of preferred stock with a par value of $0.01 per share, in one or more series. As of October 31, 2017 and July 31, 2017, there were no shares of preferred stock issued and outstanding.

Common Stock

As of October 31, 2017, 100,000,000 shares of common stock with a par value of $0.01 per share are authorized for issuance.

Schedule TO and Warrant Exercises

On October 10, 2017, we closed a tender offer to amend and exercise outstanding warrants to purchase shares of our Common Stock. Specifically, we filed a Schedule TO with the SEC on August 25, 2017 offering to (i) reduce the exercise price of the warrants to purchase 4,104,980 shares of Common Stock issued to investors participating in our private placement financing completed on August 29, 2014, as amended (the “2014 Warrants”) from $0.75 per share to $0.60 per share of Common Stock in cash, (ii) reduce the exercise price of outstanding warrants to purchase 1,986,101 shares of Common Stock issued to investors participating in our private placement financing completed on November 23, 2015 (the “2015 Warrants”) from $0.45 per share to $0.40 per share of Common Stock in cash, (iii) reduce the exercise price of the outstanding warrants to purchase 1,572,941 shares of Common Stock issued to investors participating in our private placement financing completed on January 23, 2017 (the “2017 Warrants”, together with the 2014 Warrants and 2015 Warrants, the “Original Warrants”) from $1.25 per share to $0.85 per share of Common Stock in cash, (iv) shorten the exercise period of the Original Warrants so that they expired concurrently with the expiration of the Offer to Amend and Exercise at 5:00 p.m. (Pacific Time) on September 25, 2017 (“Expiration Date”) unless extended until the Subsequent Expiration Date (as defined below), (v) delete the cashless exercise provisions in the Original Warrants and (vi) delete the price-based anti-dilution provisions contained in the 2015 Warrants.

Additionally, we requested the holders of a majority of the shares issuable upon exercise of the 2014 Warrants (the “2014 Requisite Majority”), 2015 Warrants (the “2015 Requisite Majority”) and 2017 Warrants (the “2017 Requisite Majority”) to approve an amendment of all of the outstanding 2014 Warrants, 2015 Warrants and 2017 Warrants, respectively, to amend such Original Warrants in the same manner as set forth above (the “Aggregate Warrant Amendment”), except the Expiration Date would be extended until October 10, 2017 (the “Subsequent Expiration Date”) if such Aggregate Warrant Amendment was approved with respect to such class of Original Warrants. The 2015 Requisite Majority approved an amendment of all of the outstanding 2015 Warrants and holders of 2015 Warrants had until the Subsequent Expiration Date to exercise their 2015 Warrants (the “Subsequent Offer Period”).

The Offer to Amend and Exercise with respect to the 2014 Warrants and 2017 Warrants expired on the Expiration Date of September 25, 2017. As of September 25, 2017, 1,491,649 shares of Common Stock were issued upon exercise of 2014 Warrants, 1,599,135 shares of Common Stock were issued upon exercise of 2015 Warrants and 1,396,470 shares of Common Stock were issued upon exercise of 2017 Warrants, for aggregate gross proceeds to us of approximately $2,720,000. During the Subsequent Offer Period, 2015 Warrants to purchase 268,909 shares of Common Stock were exercised for aggregate gross proceeds to us of approximately $107,000. 2014 Warrants to purchase 2,533,331 shares of Common Stock and 2017 Warrants to purchase 176,471 shares of Common Stock at exercise prices of $0.75 per share and $1.25 per share, respectively, continue to remain outstanding and no 2015 Warrants remain outstanding.

Original Warrants (including 2015 Warrants exercised during the Subsequent Offer Period) to purchase an aggregate of 4,756,163 shares of Common Stock were tendered and exercised in the Offer to Amend and Exercise for aggregate net proceeds to us of approximately $2,632,000. Garden State Securities Inc. assisted the Company as warrant solicitation agents with respect to the 2017 Warrants.

Due to the reduction in exercise price for the Original Warrants issued in connection with the Schedule TO, we determined it was appropriate to record $876,000 of expense in the condensed consolidated statement of operations for the inducement to exercise the Original Warrants.

Additional Warrant Exercise

During the three months ended October 31, 2017, there was a net exercise on 198,057 warrants which resulted in the issuance of 82,545 shares of our common stock. As these warrants were net exercised, as permitted under the respective warrant agreement, we did not receive any cash proceeds. The warrants were issued in connection with the Original Warrants discussed above.

Other Activity

During the three months ended October 31, 2017, we entered into a two-year service agreement for business development services. In accordance with the agreement we issued 50,000 shares of common stock, with a value of $51,000. The value was capitalized to prepaid expense and is being amortized over the term of the agreement. During the three months ended October 31, 2017, we recognized $3,000 of expense related to these services.

On April 13, 2016, we entered into a two-year service agreement for general financial advisory services. In accordance with the agreement we issued 250,000 shares of common stock, with a value of $290,000. The value was capitalized to prepaid expense and is being amortized over the term of the agreement. During the three months ended October 31, 2017 and 2016, we recognized $36,000 of expense related to these services.

10. Share-Based Compensation

Restricted Stock Units

During the three months ended October 31, 2017, the Compensation Committee of the Board of Directors authorized the issuance of 150,000 Restricted Stock Units (“RSUs”) to Janet Risi Field, a member of our board of directors. 50% of the RSUs will vest on the earlier of the date of our annual meeting of stockholders held in 2018 or January 15, 2018 and 50% of the RSUs will vest on the earlier of the date of our annual meeting of stockholders held in 2019 or January 15, 2019. Each RSU represents the right to receive one share of common stock, issuable at the time the RSU subsequently settles, as set forth in the Restricted Stock Unit Agreement.

During the three months ended October 31, 2017, we issued 300,000 RSUs to purchase common stock to third-party consultants for business development services. The RSUs vest based on performance conditions if sales milestones are achieved. We currently do not expect the 300,000 RSUs to vest.

Of the 2,485,000 RSUs outstanding, we currently expect 1,300,000 to vest. As of October 31, 2017, there was $1,278,000 of unrecognized non-cash compensation cost related to RSUs we expect to vest, which will be recognized over a weighted average period of 3.02 years.

For the three months ended October 31, 2017 and 2016, share-based compensation expense for RSUs was $312,000 and $52,000, respectively.

Stock Option Plans

In February 2016, we amended and restated our 2007 Equity Incentive Plan, or the Plan, to, among other changes, increase the number of shares of common stock issuable under the Plan by 4,000,000 shares and extend the term of the Plan until February 4, 2026. The Plan provides for the grant of incentive and non-qualified stock options, as well as other share-based payment awards, to our employees, directors, consultants and advisors. These awards have up to a 10-year contractual life and are subject to various vesting periods, as determined by the Compensation Committee of the Board of Directors. Our 2007 Equity Incentive Plan is the only active plan pursuant to which options to acquire common stock or restricted stock awards can be granted and are currently outstanding. As of October 31, 2017, there were approximately 561,000 shares available for issuance under the Plan.

During the three months ended October 31, 2017, the Compensation Committee of the Board of Directors authorized the issuance of 200,000 options to purchase common stock to Janet Risi Field, a member of our board of directors. 50% of the options will vest on the earlier of the date of our annual meeting of stockholders held in 2018 or January 15, 2018 and 50% of the options will vest on the earlier of the date of our annual meeting of stockholders held in 2019 or January 15, 2019.

During the three months ended October 31, 2016, we issued 100,000 options to purchase common stock to a member of our Scientific Advisory Board. The options vested quarterly over one year and carry a five-year term.

None of the options granted to our directors were granted pursuant to any compensatory, bonus, or similar plan maintained or otherwise sponsored by the Company.

A summary of our stock option activity is as follows:

	Shares		Weighted- Average Exercise Price		Aggregate Intrinsic Value
Outstanding at July 31, 2017		5,759,843	$	1.25	$	1,120,000
Granted		200,000	$	1.21
Exercised		—	$	—
Cancelled		—	$	—
Outstanding at October 31, 2017		5,959,843	$	1.25	$	544,000

The weighted-average remaining contractual term of options outstanding at October 31, 2017 was 5.55 years.

At October 31, 2017, options to purchase 3,163,593 shares of common stock were exercisable. These options had a weighted-average exercise price of $1.35, an aggregate intrinsic value of $432,000, and a weighted average remaining contractual term of 3.15 years. The weighted average grant date fair value for options granted during the three months ended October 31, 2017 was $0.85. The total unrecognized compensation cost related to unvested stock option grants as of October 31, 2017 was approximately $1,675,000 and the weighted average period over which these grants are expected to vest is 3.04 years.

For the three months ended October 31, 2017 and 2016, share-based compensation expense for stock options was $395,000 and $226,000 respectively.

We use the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method. The fair value of stock options was estimated at the grant date using the following weighted average assumptions:

	For the three months ended October 31,
	2017			2016
Volatility		86.98	%		74.71	%
Risk-free interest rate		1.80	%		0.93	%
Dividend yield		0.0	%		0.0	%
Expected life		5.45	years		2.81	years

Volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility.

The risk-free interest rates used in the Black-Scholes calculations are based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve.

We have never paid dividends on our common stock and do not anticipate paying dividends on our common stock in the foreseeable future. Accordingly, we have assumed no dividend yield for purposes of estimating the fair value of our share-based compensation.

The weighted average expected life of options was estimated using the average of the contractual term and the weighted average vesting term of the options. Certain options granted to consultants are subject to variable accounting treatment and are required to be revalued until vested.

Stock-based compensation expense is based on awards ultimately expected to vest, and therefore is reduced by expected forfeitures. We have not had significant forfeitures of stock options granted to employees and directors as a significant number of our historical stock option grants were fully vested at issuance or were issued with short vesting provisions. Therefore, we have estimated the forfeiture rate of our outstanding stock options as zero.

11. Recent Accounting Pronouncements

In July 2017, the Financial Accounting Standards Board (“FASB”) issued a two-part Accounting Standards Update (“ASU”) No. 2017-11, I. Accounting for Certain Financial Instruments With Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception (“ASU 2017-11”). ASU 2017-11 amends guidance in FASB ASC 260, Earnings Per Share, FASB ASC 480, Distinguishing Liabilities from Equity, and FASB ASC 815, Derivatives and Hedging. The amendments in Part I of ASU 2017-11 change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. The amendments in Part II of ASU 2017-11 re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. ASU 2017-11 is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. We are evaluating the effect that this update will have on our consolidated financial statements and related disclosures.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) which amended the existing accounting standards for revenue recognition. ASU 2014-09 establishes principles for recognizing revenue upon the transfer of promised goods or services to customers, in an amount that reflects the expected consideration received in exchange for those goods or services. In July 2015, the FASB deferred the effective date for annual reporting periods beginning after December 15, 2017. We expect to adopt ASU 2014-09 in the first fiscal quarter of 2019. We currently do not have any material revenue contracts with customers and will review any new contracts entered into prior to the adoption of the new standard. We are evaluating the effect that this update will have on our consolidated financial statements and related disclosures.

12. Subsequent Events

Subsequent to October 31, 2017, we wrote-off $26,000 of inventory destroyed in a third-party warehouse fire. We are currently exploring options to recover our loss.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

All references in this Item 2 and elsewhere in this Quarterly Report to “PURE,” “we”, “our,” “us” and the “Company” refer to PURE Bioscience, Inc., a Delaware corporation, and our wholly owned subsidiary, ETI H2O, Inc., a Nevada corporation. ETI H2O, Inc. currently has no business operations and no material assets or liabilities and there have been no significant transactions related to ETI H2O, Inc. during the periods presented in the condensed consolidated financial statements contained elsewhere in this Quarterly Report.

The discussion in this section contains forward-looking statements. These statements relate to future events or our future financial performance. We have attempted to identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “should,” “would” or “will” or the negative of these terms or other comparable terminology, but their absence does not mean that a statement is not forward-looking. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which could cause our actual results to differ from those projected in any forward-looking statements we make. Several risks and uncertainties we face are discussed in more detail under “Risk Factors” in Part II, Item 1A of this Quarterly Report or in the discussion and analysis below. You should, however, understand that it is not possible to predict or identify all risks and uncertainties and you should not consider the risks and uncertainties identified by us to be a complete set of all potential risks or uncertainties that could materially affect us. You should not place undue reliance on the forward-looking statements we make herein because some or all of them may turn out to be wrong. We undertake no obligation to update any of the forward-looking statements contained herein to reflect future events and developments, except as required by law. The following discussion should be read in conjunction with the condensed consolidated financial statements and the notes to those financial statements included elsewhere in this Quarterly Report on Form 10-Q.

Overview

We are focused on developing and commercializing proprietary antimicrobial products that provide safe and cost-effective solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, we believe SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity, non-causticity, and the inability of bacteria to form a resistance to it.

Our SDC-based technology platform has potential application in a number of industries. Our near-term focus is on offering products that address food safety risks across the food industry supply chain. In 2011, the Centers for Disease Control and Prevention (CDC) reported that foodborne illnesses affect more than 48 million people annually in the U.S., causing 128,000 hospitalizations and 3,000 fatalities. The CDC estimated that more than 9 million of these foodborne illnesses were attributed to major pathogens. The CDC reported that contaminated produce was responsible for approximately 46% of the foodborne illnesses caused by pathogens and 23% of the foodborne illness-related deaths in the US between 1998 and 2008. Among the top pathogens contributing to foodborne illness in the U.S. are Norovirus, Salmonella, Campylobacter, Staphylococcus, Shiga toxin–producing Escherichia coli and Listeria. Salmonella is the leading cause of hospitalization, followed by Norovirus, and is the leading cause of deaths related to foodborne illness.

Based on these statistics, we believe there is a significant market opportunity for our safe, non-toxic and effective SDC-based solutions. We currently offer PURE^® Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors, and food transportation companies. We also offer PURE Control^® as a direct food contact processing aid. We received the required FDA approvals to market PURE Control^® as a direct food contact processing aid for raw poultry and fresh produce in December 2015 and January 2016, respectively. Because additional USDA approval was not required, we began marketing PURE Control as a direct food contact processing aid for fresh produce following our receipt of FDA approval in January 2016.

In July 2016, we received a “No Objection Letter” from the USDA’s Food Safety and Inspection Service (FSIS) granting approval for SDC-based PURE Control to be used as a spray or dip applied to poultry carcasses, parts and organs in pre-OLR (on-line reprocessing) and post chill processing of fresh poultry. In January 2017, we submitted an additional FCN to the FDA to allow use of higher SDC concentrations in poultry processing, allowing the flexibility to adjust to varying plant and processing conditions. In May 2017, we received a Final Letter from the FDA for this FCN as well as a “No Objection Letter” from the USDA’s Food Safety and Inspection Service (FSIS) granting approval for the higher concentrations of SDC-based PURE Control to be used as a spray or dip applied to poultry carcasses, parts and organs in pre-OLR (on-line reprocessing) and post chill processing of fresh poultry. We are currently focused on completing in-plant validation trials for PURE Control in pre- and post OLR poultry processing applications, which represents approximately 65 to 75% of the total processing aid market for poultry processing. We are also conducting in-plant trials to optimize the application of PURE Control in OLR to attempt to gain USDA approval for use in this stage of poultry processing.

Subject to the results of our focused in-plant validation efforts for our approved produce and poultry solutions, we intend to seek approval to utilize PURE Control as a direct food contact processing aid for raw meats, including beef and pork. In addition to our direct sales efforts with PURE Hard Surface and PURE Control, we market and sell our SDC-based products indirectly through third-party distributors.

Business Strategy

Our goal is to become a sustainable company by commercializing the SDC-based products we have developed with our proprietary technology platform. We are focused on delivering leading antimicrobial products that address food safety risks across the food industry supply chain. Key aspects of our business strategy include:

●

Expanding sales and distribution for our products into the food industry with a focus on a dual track of food safety market opportunities:

	●	*Hard Surface Disinfectant* - commercializing our current EPA registered PURE Hard Surface disinfectant and sanitizer for use in foodservice operations, food manufacturing and food transportation.

	●	*Direct Food Contact* - commercializing FDA approved PURE Control as a direct food contact processing aid for fresh produce; commercializing FDA approved PURE Control as a food processing and intervention aid for food processors treating raw poultry in pre and post OLR applications. We also intend to continue our on-going in plant trials to optimize the application of PURE Control in OLR to attempt to gain USDA approval for use in this stage of poultry processing. Additionally, subject to the results of our focused in-plant validation efforts for our approved produce and poultry solutions, we intend to seek approval to utilize PURE Control as a direct food contact processing aid for raw meats, including beef and pork.

	●	Establishing strategic alliances to maximize the commercial potential of our technology platform;

	●	Developing additional proprietary products and applications; and

	●	Protecting and enhancing our intellectual property.

In addition to our current products addressing food safety, we intend to leverage our technology platform through licensing and distribution collaborations in order to develop new products and enter into new markets that could potentially generate multiple sources of revenue.

Liquidity & Going Concern Update

Our condensed consolidated financial statements have been prepared and presented on a basis assuming we will continue as a going concern. The factors below raise substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty.

We do not have, and may never have, significant cash inflows from product sales or from other sources of revenue to fund our operations. As of October 31, 2017, we had $3,229,000 in cash and cash equivalents, and $425,000 of accounts payable. As of October 31, 2017, we have no long-term debt. In October 2017, we completed a tender offer to amend and exercise outstanding warrants held by the investors participating in our 2014, 2015 and 2017 private placement financings, resulting in net receipts of approximately $2.6 million in cash proceeds from the exercise of 4,756,163 outstanding warrants. We do not currently believe that our existing cash resources are sufficient to meet our anticipated needs over the next twelve months from the date hereof.

Financial Overview

This financial overview provides a general description of our revenue and expenses.

Revenue

We contract manufacture and sell SDC-based products for end use, and as a raw material for manufacturing use. We also license our products and technology to development and commercialization partners. Revenue is recognized when realized or realizable and earned. Any amounts received prior to satisfying revenue recognition criteria are recorded as deferred revenue.

Cost of Goods Sold

Cost of goods sold for product sales includes direct and indirect costs to manufacture products, including materials consumed, manufacturing overhead, shipping costs, salaries, benefits, reserved inventory, and related expenses of operations. Depreciation related to manufacturing is systematically allocated to inventory produced, and expensed through cost of goods sold at the time inventory is sold.

Selling, General and Administrative

Selling, general and administrative expense consists primarily of salaries and other related costs for personnel in business development, sales, finance, accounting, information technology, and executive functions. Other selling, general and administrative costs include product marketing, advertising, and trade show costs, as well as public relations and investor relations, facility costs, and legal, accounting and other professional fees.

Research and Development

Our research and development activities are focused on leveraging our technology platform to develop additional proprietary products and applications. Research and development expense consists primarily of personnel and related costs, product registration expenses, and third-party testing. We expense research and development costs as incurred.

Other Income (Expense)

We record interest income, interest expense, the change in derivative liabilities, as well as other non-operating transactions, as other income (expense) in our condensed consolidated statements of operations.

Results of Operations

Fluctuations in Operating Results

Our results of operations have fluctuated significantly from period to period in the past and are likely to continue to do so in the future. We anticipate that our results of operations will be affected for the foreseeable future by several factors that may contribute to these periodic fluctuations, including the demand for our products, the timing and amount of our product sales, and the progress and timing of expenditures related to sales and marketing, as well as product development. Due to these fluctuations, we believe that the period-to-period comparisons of our operating results are not a reliable indication of our future performance.

Comparison of the Three Months Ended October 31, 2017 and 2016

Net Product Sales

Net product sales were $464,000 and $531,000 for the three months ended October 31, 2017 and 2016, respectively. The decrease of $67,000 was primarily attributable to reduced food safety sales and fluctuations within our existing legacy customer base.

For the three months ended October 31, 2017, one individual customer accounted for 49% of our net product sales. No other individual customer accounted for 10% or more of our net product sales. The geographic breakdown of net product sales was as follows: 100% U.S.

For the three months ended October 31, 2016, one individual customer accounted for 59% of our net product sales. No other individual customer accounted for 10% or more of our net product sales. The geographic breakdown of net product sales was as follows: 100% U.S.

Cost of Goods Sold

Cost of goods sold was $146,000 and $265,000 for the three months ended October 31, 2017 and 2016, respectively. The decrease of $119,000 was primarily attributable to decreased product sales.

Gross margin as a percentage of net product sales, or gross margin percentage, was 69% and 50% for the three months ended October 31, 2017 and 2016, respectively. The increase in gross margin percentage was primarily attributable to the sale of higher margin formulations and packaging configurations of our products during the quarter ended October 31, 2017, as compared with the prior period.

Selling, General and Administrative Expense

Selling, general and administrative expense was $1,445,000 and $1,337,000 for the three months ended October 31, 2017 and 2016, respectively. The increase of $108,000 was primarily attributable to increased personnel and business development fees.

Research and Development Expense

Research and development expense was $144,000 and $248,000 for the three months ended October 31, 2017 and 2016, respectively. The decrease of $104,000 was primarily attributable to reduced spending on research supporting our FDA approvals.

Share-Based Compensation

Share-based compensation expense was $656,000 and $278,000 for the three months ended October 31, 2017 and 2016, respectively. The increase of $378,000 is primarily due to the vesting of stock options and restricted stock units granted to employees, directors and consultants supporting our selling, general and administrative, and research and development functions.

Change in Derivative Liabilities

Change in derivative liabilities for the three months ended October 31, 2017 and 2016 was a decrease of $459,000 and an increase of $159,000, respectively. The overall decrease in the derivative liability is due to updates to the assumptions used in the fair value pricing model for warrants at the date the warrants were exercised and at the end of the reporting period (See Notes 8 and 9 to the condensed consolidated financial statements included in Item 1 of this Quarterly Report on Form 10-Q).

Inducement to exercise warrants

During the three months ended October 31, 2017, we completed a tender offer to amend outstanding warrants held by the investors participating in our 2014, 2015 and 2017 private placement financings. In accordance with the terms of the tender offer the strike price for all three series of warrants was reduced. As a result, we recorded a one-time inducement expense of $876,000.

Interest Expense

Interest expense for the three months ended October 31, 2017 and 2016 was $1,000.

Other Income (Expense)

Other income for the three months ended October 31, 2017 and 2016 was $6,000 and $14,000, respectively.

Liquidity and Capital Resources

Since our inception, we have financed our operations primarily through public and private offerings of securities, debt financing, and revenue from product sales and license agreements. We have a history of recurring losses, and as of October 31, 2017 we have incurred a cumulative net loss of $111,821,000.

In October 2017, we completed a tender offer to amend and exercise outstanding warrants held by the investors participating in our 2014, 2015 and 2017 private placement financings, resulting in net receipts of approximately $2.6 million in cash proceeds from the exercise of 4,756,163 outstanding warrants. We do not currently believe that our existing cash resources are sufficient to meet our anticipated needs over the next twelve months from the date hereof. (See Notes 8 and 9 to the condensed consolidated financial statements included in Item 1 of this Quarterly Report on Form 10-Q).

We do not have, and may never have, significant cash inflows from product sales or from other sources of revenue to fund our operations. As of October 31, 2017, we had $3,229,000 in cash and cash equivalents compared with $1,640,000 in cash and cash equivalents as of July 31, 2017. The net increase in cash and cash equivalents was primarily attributable to the successful closing of the tender offer discussed above. Additionally, as of October 31, 2017, we had $637,000 of current liabilities, including $425,000 in accounts payable, compared with $2,528,000 of current liabilities, including $426,000 in accounts payable as of July 31, 2017. The net decrease in current liabilities was primarily due to the removal of the derivative liability incurred from the issuance of warrants associated with our November 2015 financing (See Notes 8 and 9 to the condensed consolidated financial statements included in Item 1 of this Quarterly Report on Form 10-Q).

In addition, from time to time we have entered into employment agreements with our executives that, under certain cases, provide for the continuation of salary and certain other benefits if these executives are terminated under specified circumstances. These agreements generally expire upon termination for cause or when we have met our obligations under these agreements. As of October 31, 2017, no events have occurred resulting in the obligation of any such payments.

Critical Accounting Policies and Estimates

The discussion and analysis of our financial condition and results of operations are based on our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures. We evaluate our estimates on an ongoing basis. We base our estimates on historical experience and on other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

In addition, the condensed consolidated financial statements included in this Quarterly Report have been prepared and presented on a basis assuming we will continue as a going concern. Until we can generate significant cash from operations, we expect to continue to fund our operations with the proceeds of offerings of our equity and debt securities. However, we cannot assure you that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business. Further, any contracts or license arrangements we enter into to raise funds may require us to relinquish our rights to our products or technology, and we cannot assure you that we will be able to enter into any such contracts or license arrangements on acceptable terms, or at all. Having insufficient funds may require us to delay or scale back our marketing, distribution and other commercialization activities or cease our operations altogether. Our financial statements do not include any adjustment relating to recoverability or classification of recorded assets and classification of recorded liabilities.

We believe the following accounting policies and estimates are critical to aid you in understanding and evaluating our reported financial results.

Revenue Recognition

We sell our products to distributors and end users. We record revenue when we sell products to our customers, rather than when our customers resell products to third parties. When we sell products to our customers, we reduce the balance of our inventory with a corresponding charge to cost of goods sold. We do not currently have any consignment sales.

Terms of our product sales are generally FOB shipping point. Product sales are recognized when delivery of the products has occurred (which is generally at the time of shipment), title has passed to the customer, the selling price is fixed or determinable, collectability is reasonably assured and we have no further obligations. Any amounts received prior to satisfying these revenue recognition criteria are recorded as deferred revenue. We record product sales net of discounts at the time of sale and report product sales net of such discounts.

We also license our products and technology to development and commercialization partners. License fee revenue consists of product and technology license fees earned. If multiple-element arrangements require on-going services or performance, then upfront product and technology license fees under such arrangements are deferred and recognized over the period of such services or performance. Non-refundable amounts received for substantive milestones are recognized upon achievement of the milestone. Any amounts received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.

Share-Based Compensation

We grant equity-based awards under share-based compensation plans or stand-alone contracts. We estimate the fair value of share-based payment awards using the Black-Scholes option valuation model. This fair value is then amortized over the requisite service periods of the awards. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. Share-based compensation expense is based on awards ultimately expected to vest, and therefore is reduced by expected forfeitures. Changes in assumptions used under the Black-Scholes option valuation model could materially affect our net loss and net loss per share.

Impairment of Long-Lived Assets

For purposes of testing impairment, we group our long-lived assets at the lowest level for which there are identifiable cash flows independent of other asset groups. Currently, there is only one level of aggregation for our intangible assets. We assess the impairment of long-lived assets, consisting of property, plant, and equipment and our patent portfolio, whenever events or circumstances indicate that the carrying value may not be recoverable. Examples of such events or circumstances include:

●

an asset group’s ability to continue to generate income from operations and positive cash flow in future periods;

	●	loss of legal ownership or title to the asset(s);

	●	significant changes in our strategic business objectives and utilization of the asset(s); and

	●	the impact of significant negative industry or economic trends.

Additionally, on a quarterly basis we review the significant assumptions underlying our impairment assessment to determine whether our previous conclusions remain valid.

Recoverability of assets to be held and used in operations is measured by a comparison of the carrying amount of an asset to the future net cash flows expected to be generated by the assets. The factors used to evaluate the future net cash flows, while reasonable, require a high degree of judgment and the results could vary if the actual results are materially different than the forecasts. In addition, we base useful lives and amortization or depreciation expense on our subjective estimate of the period that the assets will generate revenue or otherwise be used by us. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less selling costs.

We also periodically review the lives assigned to our intangible assets to ensure that our initial estimates do not exceed any revised estimated periods from which we expect to realize cash flows from the assets. If a change were to occur in any of the above-mentioned factors or estimates, the likelihood of a material change in our reported results would increase.

Derivative Financial Instruments

We do not use derivative instruments to hedge exposures to cash flow or market or foreign currency risks.

We review the terms of the common stock, warrants and convertible debt we issue to determine whether there are derivative instruments, including embedded conversion options that are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one embedded derivative instrument, including a conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.

Derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as non-operating income or expense. When the equity or convertible debt instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the host instruments themselves, usually resulting in those instruments being recorded at a discount from their face value.

Recent Accounting Pronouncements

See Note 12 to the condensed consolidated financial statements included in Item 1 of this Quarterly Report on Form 10-Q.

Off Balance Sheet Arrangements

We do not have any off balance sheet arrangements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, or the Exchange Act, and as provided in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this Item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the rules and forms of the Securities and Exchange Commission, or SEC, and that such information is accumulated and communicated to our management, including our Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

As required by Rule 13a-15(b) under the Exchange Act, our management conducted an evaluation, under the supervision and with the participation of our Principal Executive Officer and our Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report. Based on the foregoing evaluation, our Principal Executive Officer and Principal Financial Officer concluded that as of the end of the period covered by this report our disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting

In connection with the evaluation required by Exchange Act Rule 13a-15(d), our management, under the supervision and with the participation of our Principal Executive Officer and our Principal Financial Officer, concluded that there were no changes in our internal controls over financial reporting during the three months ended October 31, 2017 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

PART II – Other Information

Item 1. Legal Proceedings

From time to time, we may become involved in various lawsuits and legal proceedings that arise in the ordinary course of our business. The impact and outcome of litigation, if any, is subject to inherent uncertainties, and any adverse result in these or other matters may arise from time to time that could harm our business. We are not currently aware of any such legal proceedings or claims to which we or our wholly owned subsidiary is a party or of which any of our property is subject that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.

Item 1A. Risk Factors

In evaluating us and our common stock, we urge you to carefully consider the risks and other information in this Quarterly Report on Form 10-Q, including the risk factor included below, as well as the risk factors disclosed in Item 1A. to Part I of our Annual Report on Form 10-K for the fiscal year ended July 31, 2017, which we filed with the SEC on October 26, 2017 (the “Form 10-K”). Other than the risk factor included below, the risks and uncertainties described in “Item 1A — Risk Factors” of our Form 10-K have not materially changed. Any of the risks discussed in this Quarterly Report on Form 10-Q, including the risk factor included below, or any of the risks disclosed in “Item 1A — Risk Factors” of our Form 10-K, as well as additional risks and uncertainties not currently known to us or that we currently deem immaterial, could materially and adversely affect our results of operations, financial condition or prospects.

Risks Related to Our Business and Industry

As a result of our historical lack of financial liquidity, we do not currently have sufficient working capital to fund our planned operations and may not be able to continue as a going concern.

We have a history of recurring losses, and as of October 31, 2017, we have incurred a cumulative net loss of approximately $112 million. As of October 31, 2017, we had $3,229,000 in cash and cash equivalents and $425,000 in accounts payable. During the three months ended October 31, 2017, our cash outflows for operating activities and for investments in patents and fixed assets were $1.04 million. As a result, our existing cash resources are not sufficient to meet our anticipated needs over the next twelve months from the date hereof, and we will need to raise additional capital to continue our operations and to implement our business plan, which capital may not be available on acceptable terms or at all.

Our capital requirements will depend on many factors, including, among others:

	●	the market acceptance of, and demand for, our products;

	●	the timing and costs of executing our sales and marketing strategies;

	●	our ability to successfully complete the in-plant validation trials requested by potential customers and our ability to convert these trials into customer orders for our products;

	●	the costs and time required to obtain the necessary regulatory approvals for our products, including the required USDA approval for use of PURE Control in OLR processing of raw poultry;

	●	the extent to which we invest in new testing and product development, including in-plant optimization trials;

	●	the extent to which our customers continue to place product orders as expected and expand their existing use of our products;

	●	the cost and time to satisfy unique customer requirements regarding validation trials or to support the value proposition and benefits of our products;

	●	the timing of vendor payments and the collection of receivables, among other factors affecting our working capital;

	●	our ability to control the timing and amount of our operating expenses, including the costs to attract and retain personnel with the skills required to implement our business plan; and

	●	the costs to file, prosecute and defend our intellectual property rights.

The above factors, along with our history and near term forecast of incurring net losses and negative operating cash flows, raise substantial doubt about our ability to continue as a going concern. If we do not obtain additional capital from external sources, we will not have sufficient working capital to fund our planned operations or be able to continue as a going concern. We cannot assure you that additional financing will be available when needed or that, if available, we can obtain financing on terms favorable to us or to our stockholders. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business. Further, any contracts or license arrangements we enter into to raise funds may require us to relinquish our rights to our products or technology, and we cannot assure you that we will be able to enter into any such contracts or license arrangements on acceptable terms, or at all. Having insufficient funds may require us to delay or scale back our marketing, distribution and other commercialization activities or cease our operations altogether.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

None.

Item 6. Exhibits

The following Exhibits are filed as part of this report pursuant to Item 601 of Regulation S-K:

3.1		Certificate of Incorporation of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.1 of the Annual Report on Form 10-K filed with the SEC on October 29, 2012)

3.1.1		Certificate of Amendment to Certificate of Incorporation of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.1.1 of the Annual Report on Form 10-K filed with the SEC on October 29, 2012)

3.2		Bylaws of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.2 to the Annual Report on Form 10-K, filed with the SEC on October 29, 2012)

3.2.1		Amendment to the Bylaws of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.2.1 to the Annual Report on Form 10-K, filed with the SEC on October 29, 2012)

4.1		Form of Investor Warrant (incorporated by reference to Exhibit 4.5 to the Current Report on Form 8-K, filed with the SEC on September 2, 2009)

4.2		Wharton Capital Markets LLC Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K, filed with the SEC on March 16, 2012)

4.3		Form of Underwriter’s Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K, filed with the SEC on September 13, 2012)

4.4		Morrison & Foerster LLP Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K, filed with the SEC on January 31, 2013)

4.5		Form of Investor Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K, filed with the SEC April 23, 2013)

4.6		Form of Investor Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K, filed with the SEC August 27, 2014)

4.7		Form of Five-Year Warrant (incorporated by reference to Exhibit 4.11 to the Company’s Annual Report on Form 10-K, filed with the SEC on October 28, 2015)

4.8		Form of Investor Warrant in 2016 Private Placement Financing (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K, filed with the SEC December 7, 2016)

4.9		Form of Placement Agent Warrant in 2016 Private Placement Financing (incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K, filed with the SEC December 7, 2016)

4.10		Form of 2014 Amended Warrant (incorporated by reference to Exhibit (a)(1)(F) to the Company’s Schedule TO filed on August 25, 2017)

4.11		Form of 2015 Amended Warrant (incorporated by reference to Exhibit (a)(1)(G) to the Company’s Schedule TO filed on August 25, 2017)

4.12		Form of 2017 Amended Warrant (incorporated by reference to Exhibit (a)(1)(H) to the Company’s Schedule TO filed on August 25, 2017)

10.26		Form of Amendment and Waiver, dated August 23, 2017, by and between the Company and that certain holder party thereto (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the SEC on August 25, 2017)

31.1 *		Certification of Chief Executive Officer, pursuant to Rule 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2 *		Certification of Principal Financial Officer, pursuant to Rule 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1 *		Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2 *		Certification of Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101 *		The following materials from the Company’s Quarterly Report on Form 10-Q for the quarterly period ended October 31, 2017, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets at October 31, 2017 and July 31, 2017; (ii) Condensed Consolidated Statements of Operations for the three months ended October 31, 2017 and 2016; (iii) Condensed Consolidated Statements of Cash Flows for the three months ended October 31, 2017 and 2016; and (iv) Notes to Condensed Consolidated Financial Statements.

*	Filed herewith.

#	Management contract or compensatory plan or arrangement

Signatures

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	PURE BIOSCIENCE, INC.

Date: December 14, 2017	By:	/s/ HENRY R. LAMBERT
		Henry R. Lambert, Chief Executive Officer (Principal Executive Officer)

Date: December 14, 2017	By:	/s/ MARK S. ELLIOTT
		Mark S. Elliott, Vice President, Finance
		(Principal Financial and Accounting Officer)

EX-31.1 2 ex31-1.htm

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, Henry R. Lambert, Chief Executive Officer of PURE Bioscience, Inc., certify that:

1.	I have reviewed this report on Form 10-Q of PURE Bioscience, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: December 14, 2017	By:	/s/ HENRY R. LAMBERT
		Henry R. Lambert
		Chief Executive Officer
		(Principal Executive Officer)

EX-31.2 3 ex31-2.htm

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Mark S. Elliott, Vice President, Finance and Principal Financial and Accounting Officer of PURE Bioscience, Inc., certify that:

1.	I have reviewed this report on Form 10-Q of PURE Bioscience, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: December 14, 2017	By:	/s/ MARK S. ELLIOTT
		Mark S. Elliott
		Vice President, Finance
		(Principal Financial and Accounting Officer)

EX-32.1 4 ex32-1.htm

Exhibit 32.1

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and 18 U.S.C. § 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Pure Bioscience, Inc. (the “Company”) hereby certifies, to such officer’s knowledge, that:

	(i)	the accompanying report on Form 10-Q of the Company for the period ended October 31, 2017, to which this Certificate is attached (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

	(ii)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: December 14, 2017

By:

/s/ Henry R. Lambert

Henry R. Lambert

Chief Executive Officer

(Principal Executive Officer)

A signed original of this written statement required by Section 906 has been provided to Pure Bioscience, Inc. and will be retained by Pure Bioscience, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

This certification has not been, and shall not be deemed, “filed” with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Pure Bioscience, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

EX-32.2 5 ex32-2.htm

Exhibit 32.2

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

	(i)	the accompanying report on Form 10-Q of the Company for the period ended October 31, 2017, to which this Certificate is attached (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

	(ii)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: December 14, 2017

By:

/s/ Mark S. Elliott

Mark S. Elliott

Vice President, Finance

(Principal Financial and Accounting Officer)

EX-101.INS 6 pure-20171031.xml XBRL INSTANCE FILE 0001006028 2017-07-31 0001006028 2017-08-01 2017-10-31 0001006028 PURE:TwoThousandAndSevenEquityIncentivePlanMember 2016-02-01 2016-02-29 0001006028 PURE:TwoThousandFifteenPrivatePlacementFinancingMember PURE:OctoberClosingDateMember PURE:FiveYearsMember 2015-10-23 0001006028 PURE:TwoThousandFifteenPrivatePlacementFinancingMember PURE:OctoberClosingDateMember PURE:SixMonthsMember 2015-10-23 0001006028 PURE:TwoThousandFifteenPrivatePlacementFinancingMember PURE:NovemberClosingDateMember PURE:FiveYearsMember 2015-11-22 2015-11-23 0001006028 PURE:TwoThousandFifteenPrivatePlacementFinancingMember PURE:NovemberClosingDateMember PURE:FiveYearsMember 2015-11-23 0001006028 PURE:TwoThousandFifteenPrivatePlacementFinancingMember PURE:OctoberClosingDateMember PURE:FiveYearsMember 2015-10-22 2015-10-23 0001006028 PURE:TwoThousandFifteenPrivatePlacementFinancingMember PURE:OctoberClosingDateMember PURE:SixMonthsMember 2015-10-22 2015-10-23 0001006028 PURE:TwoThousandFifteenPrivatePlacementFinancingMember PURE:NovemberClosingDateMember PURE:SixMonthsMember 2015-11-22 2015-11-23 0001006028 PURE:TwoThousandFifteenPrivatePlacementFinancingMember PURE:SixMonthWarrantMember 2016-07-31 0001006028 PURE:TwoThousandFifteenPrivatePlacementFinancingMember PURE:NovemberClosingDateMember PURE:SixMonthsMember 2015-11-23 0001006028 PURE:TwoYearServiceAgreementOneMember 2016-04-12 2016-04-13 0001006028 2016-08-01 2016-10-31 0001006028 2017-10-31 0001006028 PURE:WarrantLiabilityMember 2017-07-31 0001006028 PURE:TwoThousandFifteenPrivatePlacementFinancingMember 2017-10-31 0001006028 PURE:TwoYearServiceAgreementOneMember 2017-08-01 2017-10-31 0001006028 PURE:TwoYearServiceAgreementOneMember 2016-08-01 2016-10-31 0001006028 us-gaap:RestrictedStockUnitsRSUMember 2017-08-01 2017-10-31 0001006028 us-gaap:RestrictedStockUnitsRSUMember 2016-08-01 2016-10-31 0001006028 us-gaap:RestrictedStockUnitsRSUMember PURE:BoardOfDirectorsMember 2017-08-01 2017-10-31 0001006028 us-gaap:RestrictedStockUnitsRSUMember 2017-10-31 0001006028 PURE:TwoThousandFourteenWarrantMember 2014-08-29 0001006028 PURE:TwoThousandFourteenWarrantMember us-gaap:MaximumMember 2014-08-29 0001006028 PURE:TwoThousandFourteenWarrantMember us-gaap:MinimumMember 2014-08-29 0001006028 PURE:TwoThousandFifteenWarrantMember us-gaap:MaximumMember 2015-11-23 0001006028 PURE:TwoThousandFifteenWarrantMember us-gaap:MinimumMember 2015-11-23 0001006028 PURE:TwoThousandSeventeenWarrantMember 2017-01-23 0001006028 PURE:TwoThousandSeventeenWarrantMember us-gaap:MaximumMember 2017-01-23 0001006028 PURE:TwoThousandSeventeenWarrantMember us-gaap:MinimumMember 2017-01-23 0001006028 PURE:TwoThousandFourteenWarrantMember 2017-09-25 0001006028 PURE:TwoThousandFiveteenWarrantMember 2017-09-25 0001006028 PURE:TwoThousandSeventeenWarrantMember 2017-09-25 0001006028 PURE:TwoThousandSeventeenWarrantMember 2017-09-24 2017-09-25 0001006028 PURE:TwoThousandFiveteenWarrantMember 2017-10-31 0001006028 PURE:TwoThousandFiveteenWarrantMember 2017-08-01 2017-10-31 0001006028 PURE:TwoThousandFourteenWarrantMember 2017-10-31 0001006028 PURE:TwoThousandSeventeenWarrantMember 2017-10-31 0001006028 PURE:TwoThousandFiveteenWarrantMember PURE:GardenStateSecuritiesIncMember 2017-10-31 0001006028 PURE:TwoThousandFiveteenWarrantMember PURE:GardenStateSecuritiesIncMember 2017-08-01 2017-10-31 0001006028 PURE:BoardOfDirectorsMember PURE:JanuaryFifteenTwoThousandAndNineteenMember 2017-08-01 2017-10-31 0001006028 PURE:BoardOfDirectorsMember PURE:JanuaryFifteenTwoThousandAndEighteenMember 2017-08-01 2017-10-31 0001006028 PURE:TwoThousandAndSevenEquityIncentivePlanMember 2017-10-31 0001006028 PURE:StockOptionPlansMember PURE:BoardOfDirectorsMember 2017-08-01 2017-10-31 0001006028 PURE:StockOptionPlansMember PURE:BoardOfDirectorsMember PURE:JanuaryFifteenTwoThousandAndEighteenMember 2017-08-01 2017-10-31 0001006028 PURE:StockOptionPlansMember PURE:BoardOfDirectorsMember PURE:JanuaryFifteenTwoThousandAndNineteenMember 2017-08-01 2017-10-31 0001006028 PURE:StockOptionPlansMember 2017-08-01 2017-10-31 0001006028 PURE:StockOptionPlansMember 2016-08-01 2016-10-31 0001006028 PURE:StockOptionPlansMember 2017-10-31 0001006028 2017-12-12 0001006028 2016-10-31 0001006028 2016-07-31 0001006028 PURE:WarrantLiabilityMember 2017-08-01 2017-10-31 0001006028 PURE:WarrantLiabilityMember 2017-10-31 0001006028 PURE:TwoThousandFifteenPrivatePlacementFinancingMember 2017-09-25 0001006028 PURE:TwoThousandFifteenPrivatePlacementFinancingMember 2017-09-24 2017-09-25 0001006028 PURE:TwoThousandFifteenPrivatePlacementFinancingMember 2017-10-10 0001006028 PURE:TwoThousandFifteenPrivatePlacementFinancingMember 2017-10-09 2017-10-10 0001006028 us-gaap:WarrantMember 2017-08-01 2017-10-31 0001006028 us-gaap:RestrictedStockUnitsRSUMember PURE:ThirdPartyConsultantsMember 2017-08-01 2017-10-31 0001006028 PURE:StockOptionPlansMember PURE:ScientificAdvisoryBoardMember 2016-08-01 2016-10-31 0001006028 PURE:TwoThousandFifteenWarrantMember 2015-11-23 0001006028 PURE:TwoThousandFourteenWarrantAndTwoThousandAndSeventeenWarrantMember 2017-08-01 2017-10-31 0001006028 PURE:TwoYearServiceAgreementMember 2017-10-30 2017-10-31 0001006028 PURE:TwoYearServiceAgreementMember 2017-08-01 2017-10-31 0001006028 us-gaap:SubsequentEventMember PURE:ThirdPartyMember 2017-08-01 2017-10-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

1853000

0.01

5000000

0.01

100000000

63093153

67981861

63093153

67981861

PURE BIOSCIENCE, INC. 10-Q 2017-10-31 false Smaller Reporting Company PURE

6666666

8666666

2222217

2820670

4104980

1572941

1491649

1599135

1396470

268909

2533331

176471

4756163

1599135

268909

1986101

0001006028

-459000

39000 36000

1853000

-1394000

250000

50000

290000

36000

51000

3000

2018 --07-31 Q1

297000

143000

273000

274000

75000

174000

175000

2459000

3896000

548000

530000

822000

781000

3829000

5207000

426000

425000

249000

212000

2528000

637000

11000

10000

2539000

647000

631000

680000

110141000

115701000

-109482000

-111821000

1290000

4560000

3829000

5207000

464000

531000

146000

265000

1445000

1337000

144000

248000

656000

278000

2391000

2128000

-1927000

-1597000

459000

-159000

1000

6000

14000

-412000

-146000

-2339000

-1743000

64964404

64823917

-0.04

-0.03

71000

65000

459000

-159000

-154000

-117000

1000

-2000

-11000

108000

-38000

147000

-1000

-1031000

-1047000

3000

7000

9000

76000

-12000

-83000

2632000

1589000

-1130000

1640000

3229000

4064000

5194000

2000

1394000

2720000

107000

2632000

P5Y P5Y P6M P6M 2820670 20376219

1.00

1.03

0.45

0.7000

0.016

P3Y2M12D

P3Y1M6D

118057

63811

82545

459000

159000

150000

2485000 1300000

1278000

P3Y7D

312000

52000

395000

226000

300000

4000000

P10Y

561000

200000

100000

0.50

P3Y15D

0.85

P5Y6M18D

1.21

1120000

544000

0.8698

0.7471

0.0180

0.0093

0.000

P5Y5M12D

P2Y9M22D

0.75

0.60

0.45

0.40

1.25

0.85

0.75

1.25

2026-02-04

P3Y1M24D

8. Derivative Liabilities   On October 23, 2015, we completed a first closing of a private placement financing (the “2015 Private Placement Financing”), where we issued, among other securities, a warrant to purchase up to an aggregate of 6,666,666 shares of common stock with a term of five years and a warrant to purchase up to an aggregate of 8,666,666 shares of common stock with a term of six months.   On November 23, 2015, we completed a second and final closing of the 2015 Private Placement Financing, where we issued, among other securities, a warrant to purchase up to an aggregate of 2,222,217 shares of common stock with a term of five years and a warrant to purchase up to an aggregate of 2,820,670 shares of common stock with a term of six months.   We accounted for the combined 20,376,219 warrants issued in connection with the 2015 Private Placement Financing in accordance with the accounting guidance for derivatives. The applicable accounting guidance sets forth a two-step model to be applied in determining whether a financial instrument is indexed to an entity’s own stock, which would qualify such financial instruments for a scope exception. This scope exception specifies that a contract that would otherwise meet the definition of a derivative financial instrument would not be considered as such if the contract is both (i) indexed to the entity’s own stock and (ii) classified in the stockholders’ equity section of the entity’s balance sheet. We determined the warrants were ineligible for equity classification due to anti-dilution provisions set forth therein.   During the fiscal year ended July 31, 2016, (i) all 2,820,670 of the six-month warrants issued in the second and final closing were exercised, (ii) the six-month warrants issued in the first closing expired and (iii) the five-year warrants issued in the first closing were cancelled.   On September 25, 2017, we completed the first closing of a tender offer to amend and exercise outstanding warrants to purchase shares of our common stock. As a result, 1,599,135 warrants issued in connection with the 2015 Private Placement Financing were exercised. In addition, there was a net exercise on 118,057 warrants which resulted in the issuance of 63,811 shares of our common stock. The net exercised warrants were issued in connection with the 2015 Private Placement Financing. The change in fair value of the warrant liabilities on September 25, 2017 was recorded as a change in derivative liabilities in the condensed consolidated statements of operations. The fair value on the exercise date was returned to additional paid in capital and is reflected in the settlement of warrant liability section on the table in Note 8. The following assumptions were used as inputs to the fair value model at September 25, 2017: stock price of $1.00 per share and a warrant exercise price of $0.45 per share as of the valuation date; our historical stock price volatility of 70.00%; risk free interest rate on U.S. treasury notes of 1.6%; warrant expiration of 3.2 years (See Note 10 to these condensed consolidated financial statements).   On October 10, 2017, we completed a second and final closing of a tender offer to amend and exercise outstanding warrants to purchase shares of our common stock. As a result, 268,909 warrants issued in connection with the 2015 Private Placement Financing were exercised. The change in fair value of the warrant liabilities on October 10, 2017 was recorded as a change in derivative liabilities in the condensed consolidated statements of operations. The fair value on the exercise date was returned to additional paid in capital and is reflected in the settlement of warrant liability section on the table in Note 8. The following assumptions were used as inputs to the fair value model at October 10, 2017: stock price of $1.03 per share and a warrant exercise price of $0.45 per share as of the valuation date; our historical stock price volatility of 70.00%; risk free interest rate on U.S. treasury notes of 1.6%; warrant expiration of 3.1 years (See Note 10 to these condensed consolidated financial statements).   During the three months ended October 31, 2017, all warrants containing derivative features issued in connection with the 2015 Private Placement Financing were exercised.   As of October 31, 2017, the total value of the derivative liabilities was zero. The change in fair value of the warrant liabilities for the three months ended October 31, 2017 and 2016, was a decrease of $459,000 and an increase of $159,000, respectively, which was recorded as a change in derivative liabilities in the condensed consolidated statements of operations.

9. Stockholders’ Equity   Preferred Stock   As of October 31, 2017, the Company’s Board of Directors is authorized to issue 5,000,000 shares of preferred stock with a par value of $0.01 per share, in one or more series. As of October 31, 2017 and July 31, 2017, there were no shares of preferred stock issued and outstanding.   Common Stock   As of October 31, 2017, 100,000,000 shares of common stock with a par value of $0.01 per share are authorized for issuance.   Schedule TO and Warrant Exercises   On October 10, 2017, we closed a tender offer to amend and exercise outstanding warrants to purchase shares of our Common Stock. Specifically, we filed a Schedule TO with the SEC on August 25, 2017 offering to (i) reduce the exercise price of the warrants to purchase 4,104,980 shares of Common Stock issued to investors participating in our private placement financing completed on August 29, 2014, as amended (the “2014 Warrants”) from $0.75 per share to $0.60 per share of Common Stock in cash, (ii) reduce the exercise price of outstanding warrants to purchase 1,986,101 shares of Common Stock issued to investors participating in our private placement financing completed on November 23, 2015 (the “2015 Warrants”) from $0.45 per share to $0.40 per share of Common Stock in cash, (iii) reduce the exercise price of the outstanding warrants to purchase 1,572,941 shares of Common Stock issued to investors participating in our private placement financing completed on January 23, 2017 (the “2017 Warrants”, together with the 2014 Warrants and 2015 Warrants, the “Original Warrants”) from $1.25 per share to $0.85 per share of Common Stock in cash, (iv) shorten the exercise period of the Original Warrants so that they expired concurrently with the expiration of the Offer to Amend and Exercise at 5:00 p.m. (Pacific Time) on September 25, 2017 (“Expiration Date”) unless extended until the Subsequent Expiration Date (as defined below), (v) delete the cashless exercise provisions in the Original Warrants and (vi) delete the price-based anti-dilution provisions contained in the 2015 Warrants.   Additionally, we requested the holders of a majority of the shares issuable upon exercise of the 2014 Warrants (the “2014 Requisite Majority”), 2015 Warrants (the “2015 Requisite Majority”) and 2017 Warrants (the “2017 Requisite Majority”) to approve an amendment of all of the outstanding 2014 Warrants, 2015 Warrants and 2017 Warrants, respectively, to amend such Original Warrants in the same manner as set forth above (the “Aggregate Warrant Amendment”), except the Expiration Date would be extended until October 10, 2017 (the “Subsequent Expiration Date”) if such Aggregate Warrant Amendment was approved with respect to such class of Original Warrants. The 2015 Requisite Majority approved an amendment of all of the outstanding 2015 Warrants and holders of 2015 Warrants had until the Subsequent Expiration Date to exercise their 2015 Warrants (the “Subsequent Offer Period”).   The Offer to Amend and Exercise with respect to the 2014 Warrants and 2017 Warrants expired on the Expiration Date of September 25, 2017. As of September 25, 2017, 1,491,649 shares of Common Stock were issued upon exercise of 2014 Warrants, 1,599,135 shares of Common Stock were issued upon exercise of 2015 Warrants and 1,396,470 shares of Common Stock were issued upon exercise of 2017 Warrants, for aggregate gross proceeds to us of approximately $2,720,000. During the Subsequent Offer Period, 2015 Warrants to purchase 268,909 shares of Common Stock were exercised for aggregate gross proceeds to us of approximately $107,000. 2014 Warrants to purchase 2,533,331 shares of Common Stock and 2017 Warrants to purchase 176,471 shares of Common Stock at exercise prices of $0.75 per share and $1.25 per share, respectively, continue to remain outstanding and no 2015 Warrants remain outstanding.   Original Warrants (including 2015 Warrants exercised during the Subsequent Offer Period) to purchase an aggregate of 4,756,163 shares of Common Stock were tendered and exercised in the Offer to Amend and Exercise for aggregate net proceeds to us of approximately $2,632,000. Garden State Securities Inc. assisted the Company as warrant solicitation agents with respect to the 2017 Warrants.   Due to the reduction in exercise price for the Original Warrants issued in connection with the Schedule TO, we determined it was appropriate to record $876,000 of expense in the condensed consolidated statement of operations for the inducement to exercise the Original Warrants.   Additional Warrant Exercise   During the three months ended October 31, 2017, there was a net exercise on 198,057 warrants which resulted in the issuance of 82,545 shares of our common stock. As these warrants were net exercised, as permitted under the respective warrant agreement, we did not receive any cash proceeds. The warrants were issued in connection with the Original Warrants discussed above.   Other Activity   During the three months ended October 31, 2017, we entered into a two-year service agreement for business development services. In accordance with the agreement we issued 50,000 shares of common stock, with a value of $51,000. The value was capitalized to prepaid expense and is being amortized over the term of the agreement. During the three months ended October 31, 2017, we recognized $3,000 of expense related to these services.   On April 13, 2016, we entered into a two-year service agreement for general financial advisory services. In accordance with the agreement we issued 250,000 shares of common stock, with a value of $290,000. The value was capitalized to prepaid expense and is being amortized over the term of the agreement. During the three months ended October 31, 2017 and 2016, we recognized $36,000 of expense related to these services.

10. Share-Based Compensation   Restricted Stock Units   During the three months ended October 31, 2017, the Compensation Committee of the Board of Directors authorized the issuance of 150,000 Restricted Stock Units (“RSUs”) to Janet Risi Field, a member of our board of directors. 50% of the RSUs will vest on the earlier of the date of our annual meeting of stockholders held in 2018 or January 15, 2018 and 50% of the RSUs will vest on the earlier of the date of our annual meeting of stockholders held in 2019 or January 15, 2019. Each RSU represents the right to receive one share of common stock, issuable at the time the RSU subsequently settles, as set forth in the Restricted Stock Unit Agreement.   During the three months ended October 31, 2017, we issued 300,000 RSUs to purchase common stock to third-party consultants for business development services. The RSUs vest based on performance conditions if sales milestones are achieved. We currently do not expect the 300,000 RSUs to vest.   Of the 2,485,000 RSUs outstanding, we currently expect 1,300,000 to vest. As of October 31, 2017, there was $1,278,000 of unrecognized non-cash compensation cost related to RSUs we expect to vest, which will be recognized over a weighted average period of 3.02 years.   For the three months ended October 31, 2017 and 2016, share-based compensation expense for RSUs was $312,000 and $52,000, respectively.   Stock Option Plans   In February 2016, we amended and restated our 2007 Equity Incentive Plan, or the Plan, to, among other changes, increase the number of shares of common stock issuable under the Plan by 4,000,000 shares and extend the term of the Plan until February 4, 2026. The Plan provides for the grant of incentive and non-qualified stock options, as well as other share-based payment awards, to our employees, directors, consultants and advisors. These awards have up to a 10-year contractual life and are subject to various vesting periods, as determined by the Compensation Committee of the Board of Directors. Our 2007 Equity Incentive Plan is the only active plan pursuant to which options to acquire common stock or restricted stock awards can be granted and are currently outstanding. As of October 31, 2017, there were approximately 561,000 shares available for issuance under the Plan.   During the three months ended October 31, 2017, the Compensation Committee of the Board of Directors authorized the issuance of 200,000 options to purchase common stock to Janet Risi Field, a member of our board of directors. 50% of the options will vest on the earlier of the date of our annual meeting of stockholders held in 2018 or January 15, 2018 and 50% of the options will vest on the earlier of the date of our annual meeting of stockholders held in 2019 or January 15, 2019.   During the three months ended October 31, 2016, we issued 100,000 options to purchase common stock to a member of our Scientific Advisory Board. The options vested quarterly over one year and carry a five-year term.   None of the options granted to our directors were granted pursuant to any compensatory, bonus, or similar plan maintained or otherwise sponsored by the Company.   A summary of our stock option activity is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Shares</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted- Average Exercise Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Aggregate Intrinsic Value</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 52%">Outstanding at July 31, 2017</td> <td style="width: 1%"> </td> <td style="width: 1%; border-bottom: black 2.25pt double"> </td> <td style="width: 11%; border-bottom: black 2.25pt double; text-align: right">5,759,843</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">1.25</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">1,120,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">200,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1.21</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Cancelled</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">—</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding at October 31, 2017</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">5,959,843</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1.25</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">544,000</td> <td> </td></tr> </table>   The weighted-average remaining contractual term of options outstanding at October 31, 2017 was 5.55 years.    At October 31, 2017, options to purchase 3,163,593 shares of common stock were exercisable. These options had a weighted-average exercise price of $1.35, an aggregate intrinsic value of $432,000, and a weighted average remaining contractual term of 3.15 years. The weighted average grant date fair value for options granted during the three months ended October 31, 2017 was $0.85. The total unrecognized compensation cost related to unvested stock option grants as of October 31, 2017 was approximately $1,675,000 and the weighted average period over which these grants are expected to vest is 3.04 years.   For the three months ended October 31, 2017 and 2016, share-based compensation expense for stock options was $395,000 and $226,000 respectively.   We use the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method. The fair value of stock options was estimated at the grant date using the following weighted average assumptions:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="6" style="border-bottom: black 1.5pt solid"> For the three months ended October 31,</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2016</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%">Volatility</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">86.98</td> <td style="width: 3%">%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">74.71</td> <td style="width: 3%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Risk-free interest rate</td> <td> </td> <td> </td> <td style="text-align: right">1.80</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0.93</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">0.0</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0.0</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expected life</td> <td> </td> <td> </td> <td style="text-align: right">5.45</td> <td> years</td> <td> </td> <td> </td> <td style="text-align: right">2.81</td> <td> years</td></tr> </table>   Volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility.   The risk-free interest rates used in the Black-Scholes calculations are based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve.   We have never paid dividends on our common stock and do not anticipate paying dividends on our common stock in the foreseeable future. Accordingly, we have assumed no dividend yield for purposes of estimating the fair value of our share-based compensation.   The weighted average expected life of options was estimated using the average of the contractual term and the weighted average vesting term of the options. Certain options granted to consultants are subject to variable accounting treatment and are required to be revalued until vested.   Stock-based compensation expense is based on awards ultimately expected to vest, and therefore is reduced by expected forfeitures. We have not had significant forfeitures of stock options granted to employees and directors as a significant number of our historical stock option grants were fully vested at issuance or were issued with short vesting provisions. Therefore, we have estimated the forfeiture rate of our outstanding stock options as zero.

12. Subsequent Events   Subsequent to October 31, 2017, we wrote-off $26,000 of inventory destroyed in a third-party warehouse fire. We are currently exploring options to recover our loss.

Inventories consist of the following:   <table cellspacing="0" cellpadding="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">October 31, 2017</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">July 31, 2017</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%">Raw materials</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 20%; text-align: right">80,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 20%; text-align: right">82,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Finished goods</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">194,000</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">191,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">274,000</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">273,000</td> <td> </td></tr> </table>

The following table provides a reconciliation of the beginning and ending balances of the derivative liabilities for the three months ended October 31, 2017:   Fair Value of Significant Unobservable Inputs (Level 3)   <table cellspacing="0" cellpadding="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center">Warrant</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Liabilities</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%; text-align: justify">Balance at July 31, 2017</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">1,853,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Issuances</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">Settlement of warrant liabilities</td> <td> </td> <td> </td> <td style="text-align: right">(1,394,000</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Adjustments to estimated fair value</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(459,000</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">Balance at October 31, 2017</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td></tr> </table>

A summary of our stock option activity is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Shares</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted- Average Exercise Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Aggregate Intrinsic Value</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 52%">Outstanding at July 31, 2017</td> <td style="width: 1%"> </td> <td style="width: 1%; border-bottom: black 2.25pt double"> </td> <td style="width: 11%; border-bottom: black 2.25pt double; text-align: right">5,759,843</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">1.25</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">1,120,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">200,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1.21</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Cancelled</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">—</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding at October 31, 2017</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">5,959,843</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1.25</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">544,000</td> <td> </td></tr> </table>

The fair value of stock options was estimated at the grant date using the following weighted average assumptions:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="6" style="border-bottom: black 1.5pt solid"> For the three months ended October 31,</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2016</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%">Volatility</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">86.98</td> <td style="width: 3%">%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">74.71</td> <td style="width: 3%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Risk-free interest rate</td> <td> </td> <td> </td> <td style="text-align: right">1.80</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0.93</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">0.0</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0.0</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expected life</td> <td> </td> <td> </td> <td style="text-align: right">5.45</td> <td> years</td> <td> </td> <td> </td> <td style="text-align: right">2.81</td> <td> years</td></tr> </table>

3163593

1.35

432000

1675000

67981861

1. Basis of Presentation   The accompanying unaudited condensed consolidated financial statements include the consolidated accounts of PURE Bioscience, Inc. and its wholly owned subsidiary, ETI H2O Inc., a Nevada corporation. ETI H2O, Inc. currently has no business operations and no material assets or liabilities and there have been no significant transactions related to ETI H2O, Inc. during the periods presented in the condensed consolidated financial statements. All inter-company balances and transactions have been eliminated. All references to “PURE,” “we,” “our,” “us” and the “Company” refer to PURE Bioscience, Inc. and our wholly owned subsidiary.   The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, for interim financial information pursuant to the instructions to Form 10-Q and Article 10/Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the quarter ended October 31, 2017 are not necessarily indicative of the results that may be expected for other quarters or the year ending July 31, 2018. The July 31, 2017 balance sheet was derived from audited financial statements but does not include all disclosures required by GAAP and included in our Annual Report on Form 10-K. For more complete information, these unaudited financial statements and the notes thereto should be read in conjunction with the audited financial statements for the year ended July 31, 2017 included in our Annual Report on Form 10-K covering such period filed with the Securities and Exchange Commission, or SEC, on October 26, 2017.   The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.

2. Liquidity & Going Concern Uncertainty   These unaudited condensed consolidated financial statements have been prepared and presented on a basis assuming we will continue as a going concern. The factors below raise substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty.   Since our inception, we have financed our operations primarily through public and private offerings of securities, debt financing, and revenue from product sales and license agreements. We have a history of recurring losses, and as of October 31, 2017, we have incurred a cumulative net loss of $111,821,000.   We do not have, and may never have, significant cash inflows from product sales or from other sources of revenue to fund our operations. As of October 31, 2017, we had $3,229,000 in cash and cash equivalents, and $425,000 of accounts payable. As of October 31, 2017, we have no long-term debt. We do not currently believe that our existing cash resources are sufficient to meet our anticipated needs over the next twelve months from the date hereof.   Our future capital requirements depend on numerous forward-looking factors. These factors may include, but are not limited to, the following: the acceptance of, and demand for, our products; our success and the success of our partners in selling our products; our success and the success of our partners in obtaining regulatory approvals to sell our products; the costs of further developing our existing products and technologies; the extent to which we invest in new product and technology development; and the costs associated with the continued operation, and any future growth, of our business. The outcome of these and other forward-looking factors will substantially affect our liquidity and capital resources.   Until we can generate significant cash from operations, we expect to continue to fund our operations with the proceeds of offerings of our equity and debt securities. However, we cannot assure you that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business. Further, any contracts or license arrangements we enter into to raise funds may require us to relinquish our rights to our products or technology, and we cannot assure you that we will be able to enter into any such contracts or license arrangements on acceptable terms, or at all. Having insufficient funds may require us to delay or scale back our marketing, distribution and other commercialization activities or cease our operations altogether.   We do not have any unused credit facilities or other sources of capital available to us at this time. We intend to secure additional working capital through sales of additional debt or equity securities. Our intended financing initiatives are subject to risk, and we cannot provide any assurance about the availability or terms of these or any future financings.   If we are unable to obtain sufficient capital, it will have a material adverse effect on our business and operations. It could cause us to fail to execute our business plan, fail to take advantage of future opportunities, or fail to respond to competitive pressures or customer requirements. It also may require us to significantly modify our business model and operations to reduce spending to a sustainable level, which may include delaying, scaling back or eliminating some or all of our ongoing and planned investments in corporate infrastructure, research and development projects, regulatory submissions, business development initiatives, and sales and marketing activities, among other investments. If adequate funds are not available when needed, we may be required to reduce or cease operations altogether.   The condensed consolidated financial statements do not include any adjustment relating to recoverability or classification of recorded assets and classification of recorded liabilities.

3. Net Loss Per Share   Basic net loss per common share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Our diluted net loss per common share is the same as our basic net loss per common share because we incurred a net loss during each period presented, and the potentially dilutive securities from the assumed exercise of all outstanding stock options, restricted stock units, and warrants would have an anti-dilutive effect. As of October 31, 2017 and 2016, the number of shares issuable upon the exercise of stock options, the vesting of restricted stock units, and the exercise of warrants, none of which are included in the computation of basic net loss per common share, was 11,680,939 and 10,719,394, respectively.

4. Comprehensive Loss   Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on marketable securities and foreign currency translation adjustments. For the three months ended October 31, 2017 and 2016, our comprehensive loss consisted only of net loss.

5. Inventory   Inventories are stated at the lower of cost or net realizable value, and net of a valuation allowance for potential excess or obsolete material. Cost is determined using the average cost method. Depreciation related to manufacturing is systematically allocated to inventory produced, and expensed through cost of goods sold at the time inventory is sold.   Inventories consist of the following:   <table cellspacing="0" cellpadding="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">October 31, 2017</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">July 31, 2017</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%">Raw materials</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 20%; text-align: right">80,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 20%; text-align: right">82,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Finished goods</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">194,000</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">191,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">274,000</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">273,000</td> <td> </td></tr> </table>

6. Impairment of Long-Lived Assets   In accordance with GAAP, if indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the carrying value of the asset to the fair value of the asset and we record the impairment as a reduction in the carrying value of the related asset and a charge to operating results. Estimating the undiscounted future cash flows associated with long-lived assets requires judgment, and assumptions could differ materially from actual results. During the three months ended October 31, 2017, no impairment of long-lived assets was indicated or recorded.

11. Recent Accounting Pronouncements   In July 2017, the Financial Accounting Standards Board (“FASB”) issued a two-part Accounting Standards Update (“ASU”) No. 2017-11, I. Accounting for Certain Financial Instruments With Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception (“ASU 2017-11”). ASU 2017-11 amends guidance in FASB ASC 260, Earnings Per Share, FASB ASC 480, Distinguishing Liabilities from Equity, and FASB ASC 815, Derivatives and Hedging. The amendments in Part I of ASU 2017-11 change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. The amendments in Part II of ASU 2017-11 re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. ASU 2017-11 is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. We are evaluating the effect that this update will have on our consolidated financial statements and related disclosures.   In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) which amended the existing accounting standards for revenue recognition. ASU 2014-09 establishes principles for recognizing revenue upon the transfer of promised goods or services to customers, in an amount that reflects the expected consideration received in exchange for those goods or services. In July 2015, the FASB deferred the effective date for annual reporting periods beginning after December 15, 2017. We expect to adopt ASU 2014-09 in the first fiscal quarter of 2019. We currently do not have any material revenue contracts with customers and will review any new contracts entered into prior to the adoption of the new standard. We are evaluating the effect that this update will have on our consolidated financial statements and related disclosures.

11680939

10719394

82000

80000

191000

194000

300000

The options vested quarterly over one year and carry a five-year term.

5759843

5959843

1.25

-876000

7. Fair Value of Financial Instruments   Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the authoritative guidance establishes a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: justify"> </td> <td style="width: 24px; text-align: justify">●</td> <td style="text-align: justify">Level 1 – Quoted prices in active markets for identical assets or liabilities.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify">●</td> <td style="text-align: justify">Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify">●</td> <td style="text-align: justify">Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</td></tr> </table>   In connection with the October and November 2015 Private Placements, we issued warrants with derivative features. These instruments were accounted for as derivative liabilities (See Note 8 to these condensed consolidated financial statements).   We used Level 3 inputs for the valuation methodology of the derivative liabilities. The estimated fair values were computed using a Monte Carlo option pricing model based on various assumptions. Our derivative liabilities are adjusted to reflect estimated fair value at each period end, with any decrease or increase in the estimated fair value being recorded in other income or expense accordingly, as adjustments to the fair value of the derivative liabilities. Various factors are considered in the pricing models we use to value the warrants, including the Company’s current stock price, the remaining life of the warrants, the volatility of the Company’s stock price, and the risk free interest rate.   The following table provides a reconciliation of the beginning and ending balances of the derivative liabilities for the three months ended October 31, 2017:   Fair Value of Significant Unobservable Inputs (Level 3)   <table cellspacing="0" cellpadding="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center">Warrant</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Liabilities</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%; text-align: justify">Balance at July 31, 2017</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">1,853,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Issuances</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">Settlement of warrant liabilities</td> <td> </td> <td> </td> <td style="text-align: right">(1,394,000</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Adjustments to estimated fair value</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(459,000</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">Balance at October 31, 2017</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td></tr> </table>

2017-09-25 198057 2632000

26000

51000

EX-101.SCH 7 pure-20171031.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Liquidity & Going Concern Uncertainty link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Impairment of Long-Lived Assets link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Derivative Liabilities link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Liquidity & Going Concern Uncertainty (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Net Loss Per Share (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Inventory - Schedule of Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Impairment of Long-Lived Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Fair Value of Financial Instruments - Schedule of Derivative Liabilities at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Derivative Liabilities (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 pure-20171031_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 pure-20171031_def.xml XBRL DEFINITION FILE EX-101.LAB 10 pure-20171031_lab.xml XBRL LABEL FILE Plan Name [Axis] 2007 Equity Incentive Plan [Member] Sale of Stock [Axis] 2015 Private Placement Financing [Member] Report Date [Axis] October Closing Date [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Five Years [Member] Six Months [Member] November Closing Date [Member] Award Type [Axis] Six-Month Warrant [Member] Two Year Service Agreement One [Member] Liability Class [Axis] Warrant Liability [Member] Restricted Stock Units RSU [Member] Related Party Transaction [Axis] Board of Directors [Member] Equity Components [Axis] 2014 Warrant [Member] Range [Axis] Maximum [Member] Minimum [Member] 2015 Warrant [Member] 2017 Warrant [Member] 2015 Warrant [Member] Legal Entity [Axis] Garden State Securities Inc [Member] January 15 2019 [Member] January 15 2018 [Member] Stock Option Plans [Member] Warrant [Member] Related Party [Axis] Third-party Consultants [Member] Title of Individual [Axis] Scientific Advisory Board [Member] 2014 Warrant and 2017 Warrant [Member] Two Year Service Agreement [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Third Party [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] Assets Current assets Cash and cash equivalents Accounts receivable Inventories, net Restricted cash Prepaid expenses Total current assets Property, plant and equipment, net Patents, net Total assets Liabilities and stockholders' equity Current liabilities Accounts payable Accrued liabilities Derivative liabilities Total current liabilities Deferred rent Total liabilities Commitments and contingencies Stockholders' equity Preferred stock, $0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding Common stock, $0.01 par value: 100,000,000 shares authorized, 67,981,861 shares issued and outstanding at October 31, 2017, and 63,093,153 shares issued and outstanding at July 31, 2017 Additional paid-in capital Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Net product sales Operating costs and expenses Cost of goods sold Selling, general and administrative Research and development Share-based compensation Total operating costs and expenses Loss from operations Other income (expense) Change in derivative liabilities Inducement to exercise warrants Interest expense, net Other income, net Total other expense Net loss Basic and diluted net loss per share Shares used in computing basic and diluted net loss per share Statement of Cash Flows [Abstract] Operating activities Net loss Adjustments to reconcile net loss to net cash used in operating activities: Amortization of stock issued for services Depreciation and amortization Change in fair value of derivative liability Inducement to exercise warrants Changes in operating assets and liabilities: Accounts receivable Inventories Prepaid expenses Accounts payable and accrued liabilities Deferred rent Net cash used in operating activities Investing activities Investment in patents Purchases of property, plant and equipment Net cash used in investing activities Financing activities Net proceeds from the exercise of warrants Net cash provided by financing activities Net (decrease) increase in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental disclosure of cash flow information Cash paid for taxes Warrant liabilities removed due to settlements Common stock issued for prepaid services Accounting Policies [Abstract] Basis of Presentation Liquidity Going Concern Uncertainty Liquidity & Going Concern Uncertainty Earnings Per Share [Abstract] Net Loss Per Share Equity [Abstract] Comprehensive Loss Inventory Disclosure [Abstract] Inventory Impairment Of Long-lived Assets Impairment of Long-Lived Assets Fair Value Disclosures [Abstract] Fair Value of Financial Instruments Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Liabilities Stockholders' Equity Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Share-Based Compensation Accounting Changes and Error Corrections [Abstract] Recent Accounting Pronouncements Subsequent Events [Abstract] Subsequent Events Schedule of Inventories Schedule of Derivative Liabilities at Fair Value Schedule of Stock Option Activity Schedule of Fair Value Assumptions Liquidity Going Concern Uncertainty Details Narrative Cumulative net loss Number of antidilutive shares Raw materials Finished goods Inventory, net, total Impairment Of Long-lived Assets Details Narrative Impairment of long-lived assets Statement [Table] Statement [Line Items] Beginning balance Issuances Settlement of warrant liabilities Adjustments to estimated fair value Ending balance Number of warrants to purchase common stock Warrant term Number of warrants issued Number of warrants exercise during the period Issuance of share of common stock Stock price Warrant expiration warrant exercise price Fair value assumption of historical stock price volatility Fair value assumption of risk free interest rate Fair value assumption of warrant expiration term Change in fair value of warrant liability Preferred stock shares authorized Preferred stock shares par value Preferred stock shares issued Preferred stock shares outstanding Common stock shares authorized Common stock shares par value Shares issued price per share Warrant expiration date Proceeds from issuance of common shares EX-101.PRE 11 pure-20171031_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Oct. 31, 2017	Dec. 12, 2017
Document And Entity Information
Entity Registrant Name	PURE BIOSCIENCE, INC.
Entity Central Index Key	0001006028
Document Type	10-Q
Document Period End Date	Oct. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--07-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		67,981,861
Trading Symbol	PURE
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2018

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Oct. 31, 2017	Jul. 31, 2017
Current assets
Cash and cash equivalents	$ 3,229,000	$ 1,640,000
Accounts receivable	143,000	297,000
Inventories, net	274,000	273,000
Restricted cash	75,000	75,000
Prepaid expenses	175,000	174,000
Total current assets	3,896,000	2,459,000
Property, plant and equipment, net	530,000	548,000
Patents, net	781,000	822,000
Total assets	5,207,000	3,829,000
Current liabilities
Accounts payable	425,000	426,000
Accrued liabilities	212,000	249,000
Derivative liabilities		1,853,000
Total current liabilities	637,000	2,528,000
Deferred rent	10,000	11,000
Total liabilities	647,000	2,539,000
Commitments and contingencies
Stockholders' equity
Preferred stock, $0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding
Common stock, $0.01 par value: 100,000,000 shares authorized, 67,981,861 shares issued and outstanding at October 31, 2017, and 63,093,153 shares issued and outstanding at July 31, 2017	680,000	631,000
Additional paid-in capital	115,701,000	110,141,000
Accumulated deficit	(111,821,000)	(109,482,000)
Total stockholders' equity	4,560,000	1,290,000
Total liabilities and stockholders' equity	$ 5,207,000	$ 3,829,000

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Oct. 31, 2017	Jul. 31, 2017
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	67,981,861	63,093,153
Common stock, shares outstanding	67,981,861	63,093,153

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Oct. 31, 2017	Oct. 31, 2016
Income Statement [Abstract]
Net product sales	$ 464,000	$ 531,000
Operating costs and expenses
Cost of goods sold	146,000	265,000
Selling, general and administrative	1,445,000	1,337,000
Research and development	144,000	248,000
Share-based compensation	656,000	278,000
Total operating costs and expenses	2,391,000	2,128,000
Loss from operations	(1,927,000)	(1,597,000)
Other income (expense)
Change in derivative liabilities	459,000	(159,000)
Inducement to exercise warrants	(876,000)
Interest expense, net	(1,000)	(1,000)
Other income, net	6,000	14,000
Total other expense	(412,000)	(146,000)
Net loss	$ (2,339,000)	$ (1,743,000)
Basic and diluted net loss per share	$ (0.04)	$ (0.03)
Shares used in computing basic and diluted net loss per share	64,964,404	64,823,917

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Oct. 31, 2017	Oct. 31, 2016
Operating activities
Net loss	$ (2,339,000)	$ (1,743,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	656,000	278,000
Amortization of stock issued for services	39,000	36,000
Depreciation and amortization	71,000	65,000
Change in fair value of derivative liability	(459,000)	159,000
Inducement to exercise warrants	876,000
Changes in operating assets and liabilities:
Accounts receivable	154,000	117,000
Inventories	(1,000)	2,000
Prepaid expenses	11,000	(108,000)
Accounts payable and accrued liabilities	(38,000)	147,000
Deferred rent	(1,000)
Net cash used in operating activities	(1,031,000)	(1,047,000)
Investing activities
Investment in patents	(3,000)	(7,000)
Purchases of property, plant and equipment	(9,000)	(76,000)
Net cash used in investing activities	(12,000)	(83,000)
Financing activities
Net proceeds from the exercise of warrants	2,632,000
Net cash provided by financing activities	2,632,000	0
Net (decrease) increase in cash and cash equivalents	1,589,000	(1,130,000)
Cash and cash equivalents at beginning of period	1,640,000	5,194,000
Cash and cash equivalents at end of period	3,229,000	4,064,000
Supplemental disclosure of cash flow information
Cash paid for taxes		2,000
Warrant liabilities removed due to settlements	1,394,000
Common stock issued for prepaid services	$ 51,000

XML 17 R6.htm IDEA: XBRL DOCUMENT

Basis of Presentation

3 Months Ended

Oct. 31, 2017

Accounting Policies [Abstract]

Basis of Presentation

1. Basis of Presentation

XML 18 R7.htm IDEA: XBRL DOCUMENT

Liquidity & Going Concern Uncertainty

3 Months Ended

Oct. 31, 2017

Liquidity Going Concern Uncertainty

Liquidity & Going Concern Uncertainty

2. Liquidity & Going Concern Uncertainty

We do not have, and may never have, significant cash inflows from product sales or from other sources of revenue to fund our operations. As of October 31, 2017, we had $3,229,000 in cash and cash equivalents, and $425,000 of accounts payable. As of October 31, 2017, we have no long-term debt. We do not currently believe that our existing cash resources are sufficient to meet our anticipated needs over the next twelve months from the date hereof.

The condensed consolidated financial statements do not include any adjustment relating to recoverability or classification of recorded assets and classification of recorded liabilities.

XML 19 R8.htm IDEA: XBRL DOCUMENT

Net Loss Per Share

3 Months Ended

Oct. 31, 2017

Earnings Per Share [Abstract]

Net Loss Per Share

3. Net Loss Per Share

XML 20 R9.htm IDEA: XBRL DOCUMENT

Comprehensive Loss

3 Months Ended

Oct. 31, 2017

Equity [Abstract]

Comprehensive Loss

4. Comprehensive Loss

XML 21 R10.htm IDEA: XBRL DOCUMENT

Inventory

3 Months Ended

Oct. 31, 2017

Inventory Disclosure [Abstract]

Inventory

5. Inventory

Inventories consist of the following:

	October 31, 2017		July 31, 2017
Raw materials	$	80,000	$	82,000
Finished goods		194,000		191,000
	$	274,000	$	273,000

XML 22 R11.htm IDEA: XBRL DOCUMENT

Impairment of Long-Lived Assets

3 Months Ended

Oct. 31, 2017

Impairment Of Long-lived Assets

Impairment of Long-Lived Assets

6. Impairment of Long-Lived Assets

XML 23 R12.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments

3 Months Ended

Oct. 31, 2017

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

7. Fair Value of Financial Instruments

	●	Level 1 – Quoted prices in active markets for identical assets or liabilities.

	●	Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

	●	Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The following table provides a reconciliation of the beginning and ending balances of the derivative liabilities for the three months ended October 31, 2017:

Fair Value of Significant Unobservable Inputs (Level 3)

	Warrant
	Liabilities
Balance at July 31, 2017	$	1,853,000
Issuances		—
Settlement of warrant liabilities		(1,394,000	)
Adjustments to estimated fair value		(459,000	)
Balance at October 31, 2017	$	—

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 24 R13.htm IDEA: XBRL DOCUMENT

Derivative Liabilities

3 Months Ended

Oct. 31, 2017

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Liabilities

8. Derivative Liabilities

During the three months ended October 31, 2017, all warrants containing derivative features issued in connection with the 2015 Private Placement Financing were exercised.

XML 25 R14.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

3 Months Ended

Oct. 31, 2017

Equity [Abstract]

Stockholders' Equity

9. Stockholders’ Equity

Preferred Stock

Common Stock

As of October 31, 2017, 100,000,000 shares of common stock with a par value of $0.01 per share are authorized for issuance.

Schedule TO and Warrant Exercises

Additional Warrant Exercise

Other Activity

XML 26 R15.htm IDEA: XBRL DOCUMENT

Share-Based Compensation

3 Months Ended

Oct. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-Based Compensation

10. Share-Based Compensation

Restricted Stock Units

For the three months ended October 31, 2017 and 2016, share-based compensation expense for RSUs was $312,000 and $52,000, respectively.

Stock Option Plans

None of the options granted to our directors were granted pursuant to any compensatory, bonus, or similar plan maintained or otherwise sponsored by the Company.

A summary of our stock option activity is as follows:

	Shares		Weighted- Average Exercise Price		Aggregate Intrinsic Value
Outstanding at July 31, 2017		5,759,843	$	1.25	$	1,120,000
Granted		200,000	$	1.21
Exercised		—	$	—
Cancelled		—	$	—
Outstanding at October 31, 2017		5,959,843	$	1.25	$	544,000

The weighted-average remaining contractual term of options outstanding at October 31, 2017 was 5.55 years.

For the three months ended October 31, 2017 and 2016, share-based compensation expense for stock options was $395,000 and $226,000 respectively.

	For the three months ended October 31,
	2017			2016
Volatility		86.98	%		74.71	%
Risk-free interest rate		1.80	%		0.93	%
Dividend yield		0.0	%		0.0	%
Expected life		5.45	years		2.81	years

The risk-free interest rates used in the Black-Scholes calculations are based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve.

XML 27 R16.htm IDEA: XBRL DOCUMENT

Recent Accounting Pronouncements

3 Months Ended

Oct. 31, 2017

Accounting Changes and Error Corrections [Abstract]

Recent Accounting Pronouncements

11. Recent Accounting Pronouncements

XML 28 R17.htm IDEA: XBRL DOCUMENT

Subsequent Events

3 Months Ended

Oct. 31, 2017

Subsequent Events [Abstract]

Subsequent Events

12. Subsequent Events

Subsequent to October 31, 2017, we wrote-off $26,000 of inventory destroyed in a third-party warehouse fire. We are currently exploring options to recover our loss.

XML 29 R18.htm IDEA: XBRL DOCUMENT

Inventory (Tables)

3 Months Ended

Oct. 31, 2017

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories consist of the following:

	October 31, 2017		July 31, 2017
Raw materials	$	80,000	$	82,000
Finished goods		194,000		191,000
	$	274,000	$	273,000

XML 30 R19.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments (Tables)

3 Months Ended

Oct. 31, 2017

Fair Value Disclosures [Abstract]

Schedule of Derivative Liabilities at Fair Value

The following table provides a reconciliation of the beginning and ending balances of the derivative liabilities for the three months ended October 31, 2017:

Fair Value of Significant Unobservable Inputs (Level 3)

	Warrant
	Liabilities
Balance at July 31, 2017	$	1,853,000
Issuances		—
Settlement of warrant liabilities		(1,394,000	)
Adjustments to estimated fair value		(459,000	)
Balance at October 31, 2017	$	—

XML 31 R20.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Tables)

3 Months Ended

Oct. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Stock Option Activity

A summary of our stock option activity is as follows:

	Shares		Weighted- Average Exercise Price		Aggregate Intrinsic Value
Outstanding at July 31, 2017		5,759,843	$	1.25	$	1,120,000
Granted		200,000	$	1.21
Exercised		—	$	—
Cancelled		—	$	—
Outstanding at October 31, 2017		5,959,843	$	1.25	$	544,000

Schedule of Fair Value Assumptions

The fair value of stock options was estimated at the grant date using the following weighted average assumptions:

	For the three months ended October 31,
	2017			2016
Volatility		86.98	%		74.71	%
Risk-free interest rate		1.80	%		0.93	%
Dividend yield		0.0	%		0.0	%
Expected life		5.45	years		2.81	years

XML 32 R21.htm IDEA: XBRL DOCUMENT

Liquidity & Going Concern Uncertainty (Details Narrative) - USD ($)	Oct. 31, 2017	Jul. 31, 2017	Oct. 31, 2016	Jul. 31, 2016
Liquidity Going Concern Uncertainty
Cumulative net loss	$ 111,821,000	$ 109,482,000
Cash and cash equivalents	3,229,000	1,640,000	$ 4,064,000	$ 5,194,000
Accounts payable	$ 425,000	$ 426,000

XML 33 R22.htm IDEA: XBRL DOCUMENT

Net Loss Per Share (Details Narrative) - shares	3 Months Ended
Net Loss Per Share (Details Narrative) - shares	Oct. 31, 2017	Oct. 31, 2016
Earnings Per Share [Abstract]
Number of antidilutive shares	11,680,939	10,719,394

XML 34 R23.htm IDEA: XBRL DOCUMENT

Inventory - Schedule of Inventories (Details) - USD ($)	Oct. 31, 2017	Jul. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 80,000	$ 82,000
Finished goods	194,000	191,000
Inventory, net, total	$ 274,000	$ 273,000

XML 35 R24.htm IDEA: XBRL DOCUMENT

Impairment of Long-Lived Assets (Details Narrative)	3 Months Ended
Impairment of Long-Lived Assets (Details Narrative)	Oct. 31, 2017 USD ($)
Impairment Of Long-lived Assets
Impairment of long-lived assets

XML 36 R25.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments - Schedule of Derivative Liabilities at Fair Value (Details) - Warrant Liability [Member]	3 Months Ended
	Oct. 31, 2017 USD ($)
Beginning balance	$ 1,853,000
Issuances
Settlement of warrant liabilities	(1,394,000)
Adjustments to estimated fair value	(459,000)
Ending balance

XML 37 R26.htm IDEA: XBRL DOCUMENT

Derivative Liabilities (Details Narrative) - USD ($)					3 Months Ended
Derivative Liabilities (Details Narrative) - USD ($)	Oct. 10, 2017	Sep. 25, 2017	Nov. 23, 2015	Oct. 23, 2015	Oct. 31, 2017	Oct. 31, 2016	Jul. 31, 2017	Jul. 31, 2016
Derivative liabilities							$ 1,853,000
Change in fair value of warrant liability					$ 459,000	$ 159,000
2015 Private Placement Financing [Member]
Number of warrants to purchase common stock	268,909	1,599,135
Number of warrants issued					20,376,219
Number of warrants exercise during the period		118,057
Issuance of share of common stock		63,811
Stock price	$ 1.03	$ 1.00
Warrant expiration warrant exercise price	$ 0.45	$ 0.45
Fair value assumption of historical stock price volatility	70.00%	70.00%
Fair value assumption of risk free interest rate	1.60%	1.60%
Fair value assumption of warrant expiration term	3 years 1 month 6 days	3 years 2 months 12 days
2015 Private Placement Financing [Member] \| Six-Month Warrant [Member]
Number of warrants issued								2,820,670
2015 Private Placement Financing [Member] \| October Closing Date [Member] \| Five Years [Member]
Number of warrants to purchase common stock				6,666,666
Warrant term				5 years
2015 Private Placement Financing [Member] \| October Closing Date [Member] \| Six Months [Member]
Number of warrants to purchase common stock				8,666,666
Warrant term				6 months
2015 Private Placement Financing [Member] \| November Closing Date [Member] \| Five Years [Member]
Number of warrants to purchase common stock			2,222,217
Warrant term			5 years
2015 Private Placement Financing [Member] \| November Closing Date [Member] \| Six Months [Member]
Number of warrants to purchase common stock			2,820,670
Warrant term			6 months

XML 38 R27.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details Narrative) - USD ($)				3 Months Ended
Stockholders' Equity (Details Narrative) - USD ($)	Oct. 31, 2017	Sep. 25, 2017	Apr. 13, 2016	Oct. 31, 2017	Oct. 31, 2016	Jul. 31, 2017	Jan. 23, 2017	Nov. 23, 2015	Aug. 29, 2014
Preferred stock shares authorized	5,000,000			5,000,000		5,000,000
Preferred stock shares par value	$ 0.01			$ 0.01		$ 0.01
Preferred stock shares issued
Preferred stock shares outstanding
Common stock shares authorized	100,000,000			100,000,000		100,000,000
Common stock shares par value	$ 0.01			$ 0.01		$ 0.01
Inducement to exercise warrants				$ 876,000
Two Year Service Agreement [Member]
Number of common shares issued for services	50,000
Value of shares issued for services	$ 51,000			3,000
Two Year Service Agreement One [Member]
Number of common shares issued for services			250,000
Value of shares issued for services			$ 290,000	$ 36,000	$ 36,000
2014 Warrant [Member]
Number of warrants to purchase common stock	2,533,331	1,491,649		2,533,331					4,104,980
Shares issued price per share	$ 0.75			$ 0.75
2014 Warrant [Member] \| Maximum [Member]
Shares issued price per share									$ 0.75
2014 Warrant [Member] \| Minimum [Member]
Shares issued price per share									$ 0.60
2015 Warrant [Member]
Number of warrants to purchase common stock								1,986,101
2015 Warrant [Member] \| Maximum [Member]
Shares issued price per share								$ 0.45
2015 Warrant [Member] \| Minimum [Member]
Shares issued price per share								$ 0.40
2017 Warrant [Member]
Number of warrants to purchase common stock	176,471	1,396,470		176,471			1,572,941
Shares issued price per share	$ 1.25			$ 1.25
Proceeds from issuance of common shares		$ 2,720,000
2017 Warrant [Member] \| Maximum [Member]
Shares issued price per share							$ 1.25
2017 Warrant [Member] \| Minimum [Member]
Shares issued price per share							$ 0.85
2014 Warrant and 2017 Warrant [Member]
Warrant expiration date				Sep. 25, 2017
2015 Warrant [Member]
Number of warrants to purchase common stock	268,909	1,599,135		268,909
Proceeds from issuance of common shares				$ 107,000
2015 Warrant [Member] \| Garden State Securities Inc [Member]
Number of warrants to purchase common stock	4,756,163			4,756,163
Proceeds from issuance of common shares				$ 2,632,000
Warrant [Member]
Number of warrants exercise during the period				198,057
Issuance of share of common stock				82,545

XML 39 R28.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
Share-Based Compensation (Details Narrative) - USD ($)	Feb. 29, 2016	Oct. 31, 2017	Oct. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options issued to purchase common stock		200,000
2007 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares increase under the plan	4,000,000
Share-based compensation, expiration date	Feb. 04, 2026
Contractual life vesting periods	10 years
Number of shares available for issuance under the plan		561,000
Stock Option Plans [Member] \| Scientific Advisory Board [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options issued to purchase common stock			100,000
Option vested description			The options vested quarterly over one year and carry a five-year term.
Board of Directors [Member] \| Stock Option Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options issued to purchase common stock		200,000
Restricted Stock Units RSU [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock units outstanding		2,485,000
Shares expected to vest		1,300,000
Unrecognized non-cash compensation costs		$ 1,278,000
Unrecognized non-cash compensation costs, weighted average period		3 years 7 days
Share-based compensation		$ 312,000	$ 52,000
Restricted Stock Units RSU [Member] \| Third-party Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted stock shares issued		300,000
Aggregate number of vested shares of common stock		300,000
Restricted Stock Units RSU [Member] \| Board of Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, share-based compensation		150,000
January 15 2018 [Member] \| Board of Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option awards vesting percentage		50.00%
January 15 2018 [Member] \| Board of Directors [Member] \| Stock Option Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option awards vesting percentage		50.00%
January 15 2019 [Member] \| Board of Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option awards vesting percentage		50.00%
January 15 2019 [Member] \| Board of Directors [Member] \| Stock Option Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option awards vesting percentage		50.00%
Stock Option Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation		$ 395,000	$ 226,000
Weighted-average contractual term of options outstanding		5 years 6 months 18 days
Stock options were exercisable		3,163,593
Exercise price		$ 1.35
Aggregate intrinsic value		$ 432,000
Weighted average contractual term		3 years 1 month 24 days
Weighted average grant date fair value for options granted		$ 0.85
Unrecognized compensation cost of unvested stock option grants		$ 1,675,000
Weighted-average contractual term of expected to vest		3 years 15 days

XML 40 R29.htm IDEA: XBRL DOCUMENT

Share-Based Compensation - Schedule of Stock Option Activity (Details)	3 Months Ended
	Oct. 31, 2017 USD ($) $ / shares shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options Outstanding Shares, Beginning Balance \| shares	5,759,843
Options Granted, Shares \| shares	200,000
Options Exercised, Shares \| shares
Options Cancelled, Shares \| shares
Options Outstanding Shares, Ending Balance \| shares	5,959,843
Weighted Average Exercise Price Outstanding, Beginning Balance \| $ / shares	$ 1.25
Weighted Average Exercise Price Granted \| $ / shares	1.21
Weighted Average Exercise Price Exercised \| $ / shares
Weighted Average Exercise Price Cancelled \| $ / shares
Weighted Average Exercise Price Outstanding, Ending Balance \| $ / shares	$ 1.25
Aggregate Intrinsic Value Outstanding, Beginning Balance \| $	$ 1,120,000
Aggregate Intrinsic Value Outstanding, Ending Balance \| $	$ 544,000

XML 41 R30.htm IDEA: XBRL DOCUMENT

Share-Based Compensation - Schedule of Fair Value Assumptions (Details)	3 Months Ended
	Oct. 31, 2017	Oct. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Volatility	86.98%	74.71%
Risk-free interest rate	1.80%	0.93%
Dividend yield	0.00%	0.00%
Expected life	5 years 5 months 12 days	2 years 9 months 22 days

XML 42 R31.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative)	3 Months Ended
Subsequent Events (Details Narrative)	Oct. 31, 2017 USD ($)
Subsequent Event [Member] \| Third Party [Member]
Write off of inventory	$ 26,000

EXCEL 43 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 44 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 45 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 47 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 67 151 1 false 29 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://purebio.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://purebio.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://purebio.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://purebio.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://purebio.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - Basis of Presentation Sheet http://purebio.com/role/BasisOfPresentation Basis of Presentation Notes 6 false false R7.htm 00000007 - Disclosure - Liquidity & Going Concern Uncertainty Sheet http://purebio.com/role/LiquidityGoingConcernUncertainty Liquidity & Going Concern Uncertainty Notes 7 false false R8.htm 00000008 - Disclosure - Net Loss Per Share Sheet http://purebio.com/role/NetLossPerShare Net Loss Per Share Notes 8 false false R9.htm 00000009 - Disclosure - Comprehensive Loss Sheet http://purebio.com/role/ComprehensiveLoss Comprehensive Loss Notes 9 false false R10.htm 00000010 - Disclosure - Inventory Sheet http://purebio.com/role/Inventory Inventory Notes 10 false false R11.htm 00000011 - Disclosure - Impairment of Long-Lived Assets Sheet http://purebio.com/role/ImpairmentOfLong-livedAssets Impairment of Long-Lived Assets Notes 11 false false R12.htm 00000012 - Disclosure - Fair Value of Financial Instruments Sheet http://purebio.com/role/FairValueOfFinancialInstruments Fair Value of Financial Instruments Notes 12 false false R13.htm 00000013 - Disclosure - Derivative Liabilities Sheet http://purebio.com/role/DerivativeLiabilities Derivative Liabilities Notes 13 false false R14.htm 00000014 - Disclosure - Stockholders' Equity Sheet http://purebio.com/role/StockholdersEquity Stockholders' Equity Notes 14 false false R15.htm 00000015 - Disclosure - Share-Based Compensation Sheet http://purebio.com/role/Share-basedCompensation Share-Based Compensation Notes 15 false false R16.htm 00000016 - Disclosure - Recent Accounting Pronouncements Sheet http://purebio.com/role/RecentAccountingPronouncements Recent Accounting Pronouncements Notes 16 false false R17.htm 00000017 - Disclosure - Subsequent Events Sheet http://purebio.com/role/SubsequentEvents Subsequent Events Notes 17 false false R18.htm 00000018 - Disclosure - Inventory (Tables) Sheet http://purebio.com/role/InventoryTables Inventory (Tables) Tables http://purebio.com/role/Inventory 18 false false R19.htm 00000019 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://purebio.com/role/FairValueOfFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://purebio.com/role/FairValueOfFinancialInstruments 19 false false R20.htm 00000020 - Disclosure - Share-Based Compensation (Tables) Sheet http://purebio.com/role/Share-basedCompensationTables Share-Based Compensation (Tables) Tables http://purebio.com/role/Share-basedCompensation 20 false false R21.htm 00000021 - Disclosure - Liquidity & Going Concern Uncertainty (Details Narrative) Sheet http://purebio.com/role/LiquidityGoingConcernUncertaintyDetailsNarrative Liquidity & Going Concern Uncertainty (Details Narrative) Details http://purebio.com/role/LiquidityGoingConcernUncertainty 21 false false R22.htm 00000022 - Disclosure - Net Loss Per Share (Details Narrative) Sheet http://purebio.com/role/NetLossPerShareDetailsNarrative Net Loss Per Share (Details Narrative) Details http://purebio.com/role/NetLossPerShare 22 false false R23.htm 00000023 - Disclosure - Inventory - Schedule of Inventories (Details) Sheet http://purebio.com/role/Inventory-ScheduleOfInventoriesDetails Inventory - Schedule of Inventories (Details) Details 23 false false R24.htm 00000024 - Disclosure - Impairment of Long-Lived Assets (Details Narrative) Sheet http://purebio.com/role/ImpairmentOfLong-livedAssetsDetailsNarrative Impairment of Long-Lived Assets (Details Narrative) Details http://purebio.com/role/ImpairmentOfLong-livedAssets 24 false false R25.htm 00000025 - Disclosure - Fair Value of Financial Instruments - Schedule of Derivative Liabilities at Fair Value (Details) Sheet http://purebio.com/role/FairValueOfFinancialInstruments-ScheduleOfDerivativeLiabilitiesAtFairValueDetails Fair Value of Financial Instruments - Schedule of Derivative Liabilities at Fair Value (Details) Details 25 false false R26.htm 00000026 - Disclosure - Derivative Liabilities (Details Narrative) Sheet http://purebio.com/role/DerivativeLiabilitiesDetailsNarrative Derivative Liabilities (Details Narrative) Details http://purebio.com/role/DerivativeLiabilities 26 false false R27.htm 00000027 - Disclosure - Stockholders' Equity (Details Narrative) Sheet http://purebio.com/role/StockholdersEquityDetailsNarrative Stockholders' Equity (Details Narrative) Details http://purebio.com/role/StockholdersEquity 27 false false R28.htm 00000028 - Disclosure - Share-Based Compensation (Details Narrative) Sheet http://purebio.com/role/Share-basedCompensationDetailsNarrative Share-Based Compensation (Details Narrative) Details http://purebio.com/role/Share-basedCompensationTables 28 false false R29.htm 00000029 - Disclosure - Share-Based Compensation - Schedule of Stock Option Activity (Details) Sheet http://purebio.com/role/Share-basedCompensation-ScheduleOfStockOptionActivityDetails Share-Based Compensation - Schedule of Stock Option Activity (Details) Details 29 false false R30.htm 00000030 - Disclosure - Share-Based Compensation - Schedule of Fair Value Assumptions (Details) Sheet http://purebio.com/role/Share-basedCompensation-ScheduleOfFairValueAssumptionsDetails Share-Based Compensation - Schedule of Fair Value Assumptions (Details) Details 30 false false R31.htm 00000031 - Disclosure - Subsequent Events (Details Narrative) Sheet http://purebio.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://purebio.com/role/SubsequentEvents 31 false false All Reports Book All Reports pure-20171031.xml pure-20171031.xsd pure-20171031_cal.xml pure-20171031_def.xml pure-20171031_lab.xml pure-20171031_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2017-01-31 true true ZIP 49 0001493152-17-014602-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-17-014602-xbrl.zip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end